Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for James E Flynn. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at James E Flynn har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af James E Flynn. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ACRS / Aclaris Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ACRS / Aclaris Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ADVM / Adverum Biotechnologies, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ADVM / Adverum Biotechnologies, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AFIB / Acutus Medical, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AFIB / Acutus Medical, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AHCO / AdaptHealth Corp. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-02-21 | DFBH | Flynn James E | 2.500.000 | 2.500.000 | 266 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AHCO / AdaptHealth Corp. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ANNX / Annexon, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ANNX / Annexon, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ARVN / Arvinas, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ARVN / Arvinas, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ATYR / aTyr Pharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATYR / aTyr Pharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AVDL / Avadel Pharmaceuticals plc – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AVDL / Avadel Pharmaceuticals plc – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-06-25 | AVDL | Flynn James E | 114.034 | 5,9922 | 114.034 | 5,9922 | 683.315 | 304 | 1.0900 | -559.017 | -81,81 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AXGN / Axogen, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AXGN / Axogen, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BDTX / Black Diamond Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-02-03 | BDTX | Flynn James E | 400.000 | 19,0000 | 400.000 | 19,0000 | 7.600.000 | 140 | 44.8 | 10.320.000 | 135,79 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BDTX / Black Diamond Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BGMS / Bio Green Med Solution, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BGMS / Bio Green Med Solution, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BOLD / Boundless Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BOLD / Boundless Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CABA / Cabaletta Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-10-29 | CABA | Flynn James E | 700.000 | 11,0000 | 700.000 | 11,0000 | 7.700.000 | 92 | 18.67 | 5.369.000 | 69,73 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CABA / Cabaletta Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CALC / CalciMedica, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-09-29 | GRAY | Flynn James E | 1.562.500 | 16,0000 | 111.607 | 224,0000 | 25.000.000 | 115 | 490 | 29.687.430 | 118,75 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CALC / CalciMedica, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CTMX / CytomX Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CTMX / CytomX Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EDIT / Editas Medicine, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2016-02-08 | EDIT | Flynn James E | 100.000 | 16,0000 | 100.000 | 16,0000 | 1.600.000 | 57 | 42.0400 | 2.604.000 | 162,75 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EDIT / Editas Medicine, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EHTH / eHealth, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EHTH / eHealth, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EWTX / Edgewise Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-03-30 | EWTX | Flynn James E | 625.000 | 16,0000 | 625.000 | 16,0000 | 10.000.000 | 1 | 32.5 | 10.312.500 | 103,12 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EWTX / Edgewise Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GBIO / Generation Bio Co. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-06-16 | GBIO | Flynn James E | 225.000 | 19,0000 | 22.500 | 190,0000 | 4.275.000 | 169 | 51.61 | -3.113.775 | -72,84 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GBIO / Generation Bio Co. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GUTS / Fractyl Health, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GUTS / Fractyl Health, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb HOWL / Werewolf Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-04 | HOWL | Flynn James E | 800.000 | 16,0000 | 800.000 | 16,0000 | 12.800.000 | 59 | 20.3100 | 3.448.000 | 26,94 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg HOWL / Werewolf Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb KNSA / Kiniksa Pharmaceuticals, Ltd. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KNSA / Kiniksa Pharmaceuticals, Ltd. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb KRRO / Korro Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-10-07 | FREQ | Flynn James E | 285.714 | 14,0000 | 285.714 | 14,0000 | 3.999.996 | 121 | 27.55 | 3.871.425 | 96,79 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KRRO / Korro Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LRMR / Larimar Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LRMR / Larimar Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MIRM / Mirum Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MIRM / Mirum Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NKTX / Nkarta, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NKTX / Nkarta, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NUVL / Nuvalent, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NUVL / Nuvalent, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PEPG / PepGen Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PEPG / PepGen Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PHGE / BiomX Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PHGE / BiomX Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb QTTB / Q32 Bio Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg QTTB / Q32 Bio Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RGNX / REGENXBIO Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RGNX / REGENXBIO Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RIGL / Rigel Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RIGL / Rigel Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RVMD / Revolution Medicines, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RVMD / Revolution Medicines, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SDGR / Schrödinger, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-02-10 | SDGR | Flynn James E | 250.000 | 17,0000 | 250.000 | 17,0000 | 4.250.000 | 365 | 105.46 | 22.115.000 | 520,35 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SDGR / Schrödinger, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SPRY / ARS Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SPRY / ARS Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SYRS / Syros Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SYRS / Syros Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TARA / Protara Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TARA / Protara Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2017-11-30 | PRTO | Flynn James E | 110.557 | 1,7500 | 110.557 | 1,7500 | 193.475 | 312 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TERN / Terns Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-02-09 | TERN | Flynn James E | 665.000 | 17,0000 | 665.000 | 17,0000 | 11.305.000 | 38 | 27.25 | 6.816.250 | 60,29 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TERN / Terns Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VNDA / Vanda Pharmaceuticals Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VNDA / Vanda Pharmaceuticals Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb XLO / Xilio Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ACRS / Aclaris Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg XLO / Xilio Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ACRS / Aclaris Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af James E Flynn som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-04 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2.599.932 | 7.321.129 | 55,07 | 3,20 | 8.319.782 | 23.427.613 | |
2025-08-04 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 3.387.539 | 9.538.945 | 55,07 | 3,20 | 10.840.125 | 30.524.624 | |
2025-08-04 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 3.387.529 | 9.538.918 | 55,07 | 3,20 | 10.840.093 | 30.524.538 | |
2025-07-01 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -370.074 | 4.887.254 | -7,04 | 18,46 | -6.831.566 | 90.218.709 | |
2025-07-01 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -370.075 | 4.887.254 | -7,04 | 18,46 | -6.831.584 | 90.218.709 | |
2025-06-20 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2.647 | 2.647 | |||||
2025-06-20 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2.647 | 2.647 | |||||
2025-03-03 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 353.249 | 1.247.054 | 39,52 | 0,93 | 328.734 | 1.160.508 | |
2025-03-03 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 353.249 | 1.247.054 | 39,52 | 0,93 | 328.734 | 1.160.508 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -9.553 | 5.257.328 | -0,18 | 17,77 | -169.757 | 93.422.719 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -9.554 | 5.257.329 | -0,18 | 17,77 | -169.775 | 93.422.736 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -7.854 | 5.266.881 | -0,15 | 17,16 | -134.775 | 90.379.678 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -7.853 | 5.266.883 | -0,15 | 17,16 | -134.757 | 90.379.712 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -223.632 | 5.274.735 | -4,07 | 18,15 | -4.058.921 | 95.736.440 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -223.632 | 5.274.735 | -4,07 | 18,15 | -4.058.921 | 95.736.440 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -40.596 | 5.498.367 | -0,73 | 17,45 | -708.400 | 95.946.504 | |
2024-11-13 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Class A Common Stock |
S - Sale | -40.596 | 5.498.367 | -0,73 | 17,45 | -708.400 | 95.946.504 | |
2024-10-24 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
S - Sale | -1.000.000 | 8.670.512 | -10,34 | 97,75 | -97.750.000 | 847.542.548 | |
2024-10-24 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
S - Sale | -1.000.000 | 8.670.512 | -10,34 | 97,75 | -97.750.000 | 847.542.548 | |
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
P - Purchase | 35.000 | 897.587 | 4,06 | 18,00 | 630.000 | 16.156.566 | |
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
P - Purchase | 35.000 | 897.587 | 4,06 | 18,00 | 630.000 | 16.156.566 | |
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 862.587 | 862.587 | |||||
2024-09-17 |
|
4 | BCAX |
Bicara Therapeutics Inc.
Common Stock |
C - Conversion | 862.587 | 862.587 | |||||
2024-07-17 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 5.883.000 | 8.938.049 | 192,57 | ||||
2024-07-17 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
M - Exercise | 5.883.000 | 8.938.049 | 192,57 | ||||
2024-06-14 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2.499 | 2.499 | |||||
2024-06-14 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
A - Award | 2.499 | 2.499 | |||||
2024-03-19 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
A - Award | 3.055.049 | 3.055.049 | |||||
2024-03-19 |
|
4 | PHGE |
BiomX Inc.
Common Stock |
A - Award | 3.055.049 | 3.055.049 | |||||
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -114.906 | 11.528.863 | -0,99 | 10,70 | -1.229.494 | 123.358.834 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -88.040 | 11.643.769 | -0,75 | 11,13 | -979.885 | 129.595.149 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -94.567 | 11.731.809 | -0,80 | 10,92 | -1.032.672 | 128.111.354 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -4.495 | 11.826.376 | -0,04 | 11,03 | -49.580 | 130.444.927 | |
2024-03-12 |
|
4 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
S - Sale | -47.992 | 11.830.871 | -0,40 | 10,92 | -524.073 | 129.193.111 | |
2024-03-08 | 3 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
11.878.863 | ||||||||
2024-03-08 | 3 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
1.709.077 | ||||||||
2024-03-08 | 3 | AHCO |
AdaptHealth Corp.
Class A Common Stock |
20.000 | ||||||||
2024-02-16 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 1.430.205 | 4.207.982 | 51,49 | 8,74 | 12.499.992 | 36.777.763 | |
2024-02-16 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 1.430.206 | 6.151.406 | 30,29 | 8,74 | 12.500.000 | 53.763.288 | |
2024-02-16 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 1.430.206 | 6.151.406 | 30,29 | 8,74 | 12.500.000 | 53.763.288 | |
2024-02-08 |
|
4 | GUTS |
Fractyl Health, Inc.
Common Stock |
C - Conversion | 76.706 | 834.254 | 10,13 | ||||
2024-02-08 |
|
4 | GUTS |
Fractyl Health, Inc.
Common Stock |
C - Conversion | 757.548 | 757.548 | |||||
2023-11-21 |
|
4 | CMAX |
CareMax, Inc.
Class A Common Stock |
M - Exercise | 12.123 | 12.123 | |||||
2023-08-01 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class A Common Stock |
J - Other | -1.600.000 | 0 | -100,00 | ||||
2023-06-20 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 8.400 | 20.822 | 67,62 | ||||
2023-06-20 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 8.400 | 12.422 | 208,85 | ||||
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -15.220 | 284.697 | -5,07 | 0,27 | -4.109 | 76.868 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -61.826 | 1.156.308 | -5,08 | 0,27 | -16.693 | 312.203 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -61.826 | 1.156.308 | -5,08 | 0,27 | -16.693 | 312.203 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -15.538 | 299.917 | -4,93 | 0,26 | -4.040 | 77.978 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -63.108 | 1.218.134 | -4,93 | 0,26 | -16.408 | 316.715 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -63.107 | 1.218.135 | -4,93 | 0,26 | -16.408 | 316.715 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6.096 | 315.455 | -1,90 | 0,25 | -1.524 | 78.864 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -24.757 | 1.281.242 | -1,90 | 0,25 | -6.189 | 320.310 | |
2022-12-30 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -24.757 | 1.281.242 | -1,90 | 0,25 | -6.189 | 320.310 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -7.136 | 321.551 | -2,17 | 0,27 | -1.927 | 86.819 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -28.977 | 1.305.999 | -2,17 | 0,27 | -7.824 | 352.620 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -28.977 | 1.305.999 | -2,17 | 0,27 | -7.824 | 352.620 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -909 | 328.687 | -0,28 | 0,28 | -255 | 92.032 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3.693 | 1.334.976 | -0,28 | 0,28 | -1.034 | 373.793 | |
2022-12-27 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3.692 | 1.334.976 | -0,28 | 0,28 | -1.034 | 373.793 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1.513 | 329.596 | -0,46 | 0,30 | -454 | 98.879 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6.143 | 1.338.669 | -0,46 | 0,30 | -1.843 | 401.601 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6.144 | 1.338.668 | -0,46 | 0,30 | -1.843 | 401.600 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1.616 | 331.109 | -0,49 | 0,31 | -501 | 102.644 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6.562 | 1.344.812 | -0,49 | 0,31 | -2.034 | 416.892 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -6.562 | 1.344.812 | -0,49 | 0,31 | -2.034 | 416.892 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -10.930 | 332.725 | -3,18 | 0,29 | -3.170 | 96.490 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -44.394 | 1.351.374 | -3,18 | 0,29 | -12.874 | 391.898 | |
2022-12-21 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -44.394 | 1.351.374 | -3,18 | 0,29 | -12.874 | 391.898 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -339 | 343.655 | -0,10 | 0,39 | -132 | 134.025 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1.375 | 1.395.768 | -0,10 | 0,39 | -536 | 544.350 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -1.375 | 1.395.768 | -0,10 | 0,39 | -536 | 544.350 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -943 | 343.994 | -0,27 | 0,38 | -358 | 130.718 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3.829 | 1.397.143 | -0,27 | 0,38 | -1.455 | 530.914 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -3.828 | 1.397.143 | -0,27 | 0,38 | -1.455 | 530.914 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -230 | 344.937 | -0,07 | 0,41 | -94 | 141.424 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -933 | 1.400.972 | -0,07 | 0,41 | -383 | 574.399 | |
2022-12-15 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
S - Sale | -934 | 1.400.971 | -0,07 | 0,41 | -383 | 574.398 | |
2022-11-14 | 3 | FLAC |
Frazier Lifesciences Acquisition Corp
Class A Ordinary Shares |
2.480.199 | ||||||||
2022-11-10 | 3 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
5.538.964 | ||||||||
2022-11-10 | 3 | SPRY |
ARS Pharmaceuticals, Inc.
Common stock |
5.538.964 | ||||||||
2022-11-07 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
P - Purchase | 650.000 | 650.000 | 33,50 | 21.775.000 | 21.775.000 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2.777.777 | 2.777.777 | 3,15 | 8.749.998 | 8.749.998 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2.777.777 | 2.777.777 | 3,15 | 8.749.998 | 8.749.998 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2.777.777 | 2.777.777 | 3,15 | 8.749.998 | 8.749.998 | ||
2022-09-20 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 2.777.777 | 2.777.777 | 3,15 | 8.749.998 | 8.749.998 | ||
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6.243 | 1.540.190 | -0,40 | 24,47 | -152.766 | 37.688.449 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6.909 | 1.704.244 | -0,40 | 24,47 | -169.063 | 41.702.851 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -155 | 1.546.433 | -0,01 | 25,08 | -3.887 | 38.784.540 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -171 | 1.711.153 | -0,01 | 25,08 | -4.289 | 42.915.717 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -11.868 | 1.546.588 | -0,76 | 25,29 | -300.142 | 39.113.211 | |
2022-06-08 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -13.132 | 1.711.324 | -0,76 | 25,29 | -332.108 | 43.279.384 | |
2022-05-11 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8.300 | 8.300 | |||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Series B Preferred Stock |
C - Conversion | -273.313 | 0 | -100,00 | ||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Series B Preferred Stock |
C - Conversion | -273.313 | 0 | -100,00 | ||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
P - Purchase | 208.333 | 476.813 | 77,60 | 12,00 | 2.499.996 | 5.721.756 | |
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
P - Purchase | 208.333 | 476.813 | 77,60 | 12,00 | 2.499.996 | 5.721.756 | |
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
C - Conversion | 268.480 | 268.480 | |||||
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
C - Conversion | 268.480 | 268.480 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Public Warrants |
J - Other | 625.000 | 625.000 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Public Warrants |
J - Other | 625.000 | 625.000 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Private Placement Warrants |
J - Other | 3.177.543 | 3.177.543 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
C - Conversion | -85.113 | 0 | -100,00 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
C - Conversion | -40 | 0 | -100,00 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
J - Other | -14.887 | 85.113 | -14,89 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class B Common Stock |
J - Other | -707.960 | 40 | -99,99 | ||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Series A Common Stock Equivalent Convertible Preferred Stock |
P - Purchase | 50.000 | 58.945 | 558,97 | 1.000,00 | 50.000.000 | 58.945.000 | |
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Series A Common Stock Equivalent Convertible Preferred Stock |
P - Purchase | 50.000 | 58.945 | 558,97 | 1.000,00 | 50.000.000 | 58.945.000 | |
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class A Common Stock |
C - Conversion | 85.113 | 85.113 | |||||
2021-11-16 |
|
4 | DFPH |
Oncology Institute, Inc.
Class A Common Stock |
C - Conversion | 40 | 40 | |||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -7.186.489 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -7.186.489 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
P - Purchase | 387.500 | 1.143.972 | 51,22 | 16,00 | 6.200.000 | 18.303.552 | |
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
P - Purchase | 387.500 | 1.143.972 | 51,22 | 16,00 | 6.200.000 | 18.303.552 | |
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 756.472 | 756.472 | |||||
2021-10-28 |
|
4 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
C - Conversion | 756.472 | 756.472 | |||||
2021-09-02 |
|
4 | AFIB |
Acutus Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 7.022 | 7.022 | |||||
2021-09-02 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 1.800 | 4.022 | 81,01 | ||||
2021-08-09 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class B Common Stock, par value $0.0001 per share |
D - Sale to Issuer | -701.250 | 4.465.000 | -13,57 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
P - Purchase | 300.000 | 2.717.628 | 12,41 | 17,00 | 5.100.000 | 46.199.676 | |
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
P - Purchase | 300.000 | 2.717.628 | 12,41 | 17,00 | 5.100.000 | 46.199.676 | |
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
C - Conversion | 2.417.628 | 2.417.628 | |||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class B Common Stock |
C - Conversion | 2.417.628 | 2.417.628 | |||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series B Preferred Stock |
C - Conversion | -4.831.384 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series B Preferred Stock |
C - Conversion | -4.831.384 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -13.011.988 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -13.011.988 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -45.716.568 | 13.011.988 | -77,84 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Series A Preferred Stock |
C - Conversion | -45.716.568 | 13.011.988 | -77,84 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 897.671 | 9.670.511 | 10,23 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 897.671 | 9.670.511 | 10,23 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 8.494.140 | 8.772.840 | 3.047,77 | ||||
2021-08-04 |
|
4 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
C - Conversion | 8.494.140 | 8.772.840 | 3.047,77 | ||||
2021-08-03 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class A Common Stock |
A - Award | 650.000 | 2.250.000 | 40,62 | 10,00 | 6.500.000 | 22.500.000 | |
2021-08-03 |
|
4 | DALS |
DA32 Life Science Tech Acquisition Corp.
Class A Common Stock |
P - Purchase | 1.600.000 | 1.600.000 | 10,00 | 16.000.000 | 16.000.000 | ||
2021-07-30 |
|
4 | NUVL |
Nuvalent, Inc.
Stock Option (Right to Buy) |
A - Award | 43.000 | 43.000 | |||||
2021-07-30 |
|
4 | NUVL |
Nuvalent, Inc.
Stock Option (Right to Buy) |
A - Award | 43.000 | 43.000 | |||||
2021-07-28 | 3 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
278.700 | ||||||||
2021-07-28 | 3 | NUVL |
Nuvalent, Inc.
Class A Common Stock |
278.700 | ||||||||
2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 680.592 | 3.438.589 | 24,68 | 14,00 | 9.528.288 | 48.140.246 | |
2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 390.836 | 1.974.638 | 24,68 | 14,00 | 5.471.704 | 27.644.932 | |
2021-07-13 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -99.325 | 0 | -100,00 | 15,81 | -1.570.328 | ||
2021-07-07 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6.837 | 99.325 | -6,44 | 15,87 | -108.496 | 1.576.188 | |
2021-07-07 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -49.239 | 106.162 | -31,69 | 16,20 | -797.426 | 1.719.294 | |
2021-07-07 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
S - Sale | -10.599 | 155.401 | -6,38 | 17,01 | -180.300 | 2.643.526 | |
2021-07-02 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 228.570 | 1.943.420 | 13,33 | 8,75 | 1.999.988 | 17.004.925 | |
2021-07-02 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 228.571 | 1.943.423 | 13,33 | 8,75 | 1.999.996 | 17.004.951 | |
2021-07-02 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
P - Purchase | 228.569 | 1.943.406 | 13,33 | 8,75 | 1.999.979 | 17.004.802 | |
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Public Warrants |
J - Other | 672.000 | 672.000 | |||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Private Placement Warrants |
A - Award | 2.916.667 | 2.916.667 | |||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class B common stock |
M - Exercise | -50.000 | 0 | -100,00 | ||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class B common stock |
M - Exercise | -3.368.750 | 0 | -100,00 | ||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
M - Exercise | 50.000 | 50.000 | |||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
M - Exercise | 3.368.750 | 3.768.750 | 842,19 | ||||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
A - Award | 400.000 | 400.000 | 10,00 | 4.000.000 | 4.000.000 | ||
2021-06-10 |
|
4 | CMAX |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
A - Award | 9.600.000 | 12.960.000 | 285,71 | 10,00 | 96.000.000 | 129.600.000 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
6% Convertible Note due 2023 |
C - Conversion | 0 | ||||||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
6% Convertible Note due 2023 |
C - Conversion | 0 | ||||||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Series B Preferred Stock |
C - Conversion | -6.457.723 | 0 | -100,00 | ||||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
P - Purchase | 1.050.000 | 1.627.148 | 181,93 | 22,00 | 23.100.000 | 35.797.256 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
P - Purchase | 450.000 | 7.484.871 | 6,40 | 22,00 | 9.900.000 | 164.667.162 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
C - Conversion | 577.148 | 577.148 | 17,60 | 10.157.805 | 10.157.805 | ||
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
C - Conversion | 577.148 | 7.034.871 | 8,94 | 17,60 | 10.157.805 | 123.813.730 | |
2021-06-03 |
|
4 | OMIC |
Singular Genomics Systems, Inc.
Common Stock |
C - Conversion | 6.457.723 | 6.457.723 | |||||
2021-05-17 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 8.300 | 8.300 | |||||
2021-05-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -15.195.094 | 0 | -100,00 | ||||
2021-05-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
P - Purchase | 800.000 | 2.552.787 | 45,64 | 16,00 | 12.800.000 | 40.844.592 | |
2021-05-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
C - Conversion | 1.752.787 | 1.752.787 | |||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -433.551 | 0 | -100,00 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -1.301.626 | 0 | -100,00 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -1.572.960 | 0 | -100,00 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 625.000 | 3.933.137 | 18,89 | 16,00 | 10.000.000 | 62.930.192 | |
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 433.551 | 3.308.137 | 15,08 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 1.301.626 | 2.874.586 | 82,75 | ||||
2021-03-30 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 1.572.960 | 1.572.960 | |||||
2021-02-18 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 32.884 | 345.167 | 10,53 | 19,00 | 624.796 | 6.558.173 | |
2021-02-18 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 133.558 | 1.401.905 | 10,53 | 19,00 | 2.537.602 | 26.636.195 | |
2021-02-18 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 133.558 | 1.401.905 | 10,53 | 19,00 | 2.537.602 | 26.636.195 | |
2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -1.717.033 | 0 | -100,00 | ||||
2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 665.000 | 2.382.033 | 38,73 | 17,00 | 11.305.000 | 40.494.561 | |
2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.717.033 | 1.717.033 | |||||
2021-02-03 | 3 | IGNYU |
Ignyte Acquisition Corp.
Common Stock |
725.000 | ||||||||
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -101.600 | 784.568 | -11,47 | 22,24 | -2.259.797 | 17.450.440 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -3.912 | 886.168 | -0,44 | 23,57 | -92.194 | 20.884.321 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -1.000 | 890.080 | -0,11 | 24,11 | -24.108 | 21.458.049 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -4.378 | 891.080 | -0,49 | 25,05 | -109.665 | 22.320.663 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -11.794 | 895.458 | -1,30 | 24,35 | -287.157 | 21.802.343 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -931 | 907.252 | -0,10 | 22,64 | -21.082 | 20.544.359 | |
2021-01-08 |
|
4 | LUMO |
LUMOS PHARMA, INC.
Common Stock |
S - Sale | -28.108 | 908.183 | -3,00 | 22,47 | -631.620 | 20.407.962 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | -2.449.761 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | -2.449.761 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | -2.449.761 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | -7.499.999 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | -7.499.999 | 0 | -100,00 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 109.612 | 312.282 | 54,08 | 15,00 | 1.644.180 | 4.684.230 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 445.194 | 1.268.344 | 54,08 | 15,00 | 6.677.910 | 19.025.160 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 445.194 | 1.268.344 | 54,08 | 15,00 | 6.677.910 | 19.025.160 | |
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 202.670 | 202.670 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 202.670 | 202.670 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 202.670 | 823.150 | 32,66 | ||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 620.480 | 620.480 | |||||
2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 620.480 | 620.480 | |||||
2020-10-01 |
|
4 | LRMR |
Larimar Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16.600 | 16.600 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -2.624.901 | 0 | -100,00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -2.624.901 | 0 | -100,00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -2.624.901 | 0 | -100,00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series B Preferred Stock |
C - Conversion | -12.809.910 | 0 | -100,00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series B Preferred Stock |
C - Conversion | -12.809.912 | 0 | -100,00 | ||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
P - Purchase | 1.562.500 | 1.853.967 | 536,08 | 16,00 | 25.000.000 | 29.663.472 | |
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 291.467 | 291.467 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 291.467 | 291.467 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 291.467 | 291.467 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 1.422.406 | 1.422.406 | |||||
2020-10-01 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 1.422.406 | 1.422.406 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Preferred Stock |
C - Conversion | -1.002.464 | 0 | -100,00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Preferred Stock |
C - Conversion | -189.366 | 0 | -100,00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Preferred Stock |
C - Conversion | -1.199.980 | 0 | -100,00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Preferred Stock |
C - Conversion | -449.992 | 0 | -100,00 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 555.556 | 2.758.000 | 25,22 | 18,00 | 10.000.008 | 49.644.000 | |
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 944.444 | 1.583.802 | 147,72 | 18,00 | 16.999.992 | 28.508.436 | |
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 1.002.464 | 2.202.444 | 83,54 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 189.366 | 639.358 | 42,08 | ||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 1.199.980 | 1.199.980 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 449.992 | 449.992 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Stock Options (Right to Buy) |
A - Award | 12.454 | 12.454 | |||||
2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
A - Award | 2.222 | 2.222 | |||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Series D Preferred Stock |
C - Conversion | -4.043.031 | 0 | -100,00 | ||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Series D Preferred Stock |
C - Conversion | -4.043.032 | 0 | -100,00 | ||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
P - Purchase | 350.000 | 808.914 | 76,27 | 17,00 | 5.950.000 | 13.751.538 | |
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
P - Purchase | 350.000 | 808.914 | 76,27 | 17,00 | 5.950.000 | 13.751.538 | |
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
C - Conversion | 458.914 | 458.914 | |||||
2020-07-28 |
|
4 | ANNX |
Annexon, Inc.
Common Stock |
C - Conversion | 458.914 | 458.914 | |||||
2020-07-22 |
|
4 | DFHT |
Deerfield Healthcare Technology Acquisitions Corp.
Class A common stock |
J - Other | 3.360.000 | 3.360.000 | 10,00 | 33.600.000 | 33.600.000 | ||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Series B Preferred Stock |
C - Conversion | -2.626.767 | 0 | -100,00 | ||||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Series B Preferred Stock |
C - Conversion | -2.626.767 | 0 | -100,00 | ||||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
P - Purchase | 500.000 | 1.209.936 | 70,43 | 18,00 | 9.000.000 | 21.778.848 | |
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
P - Purchase | 500.000 | 1.209.936 | 70,43 | 18,00 | 9.000.000 | 21.778.848 | |
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
C - Conversion | 709.936 | 709.936 | |||||
2020-07-14 |
|
4 | NKTX |
Nkarta, Inc.
Common Stock |
C - Conversion | 709.936 | 709.936 | |||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Series C Preferred Stock |
C - Conversion | -455.500 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Series B Preferred Stock |
C - Conversion | -1.093.410 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Common Stock |
P - Purchase | 225.000 | 1.186.215 | 23,41 | 19,00 | 4.275.000 | 22.538.085 | |
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Common Stock |
C - Conversion | 257.883 | 961.215 | 36,67 | ||||
2020-06-16 |
|
4 | GBIO |
Generation Bio Co.
Common Stock |
C - Conversion | 703.332 | 703.332 | |||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-06-08 | 3 | LRMR |
Larimar Therapeutics, Inc.
Common Stock |
12.182.500 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1.872.338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1.872.338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1.872.338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1.872.338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1.872.338 | ||||||||
2020-03-20 | 3 | LUMO |
NEWLINK GENETICS CORP
Common Stock |
1.872.338 | ||||||||
2020-03-17 |
|
4 | DFPH |
DFP HEALTHCARE ACQUISITIONS CORP.
Class A common stock |
J - Other | 2.500.000 | 2.500.000 | 10,00 | 25.000.000 | 25.000.000 | ||
2020-03-17 |
|
4 | DFPH |
DFP HEALTHCARE ACQUISITIONS CORP.
Class A common stock |
J - Other | 2.500.000 | 2.500.000 | 10,00 | 25.000.000 | 25.000.000 | ||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series C Preferred Stock |
C - Conversion | -498.795 | 0 | -100,00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series C Preferred Stock |
C - Conversion | -997.589 | 0 | -100,00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
P - Purchase | 300.000 | 798.795 | 60,14 | 17,00 | 5.100.000 | 13.579.515 | |
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
P - Purchase | 300.000 | 798.795 | 60,14 | 17,00 | 5.100.000 | 13.579.515 | |
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
C - Conversion | 498.795 | 498.795 | |||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
C - Conversion | 997.589 | 997.589 | |||||
2020-02-10 |
|
4 | SDGR |
Schrodinger, Inc.
Series E Preferred Stock |
C - Conversion | -10.063.061 | 0 | -100,00 | ||||
2020-02-10 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
P - Purchase | 250.000 | 250.000 | 17,00 | 4.250.000 | 4.250.000 | ||
2020-02-10 |
|
4 | SDGR |
Schrodinger, Inc.
Common Stock |
C - Conversion | 1.346.167 | 1.346.167 | |||||
2020-02-03 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.142.361 | 0 | -100,00 | ||||
2020-02-03 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
P - Purchase | 400.000 | 778.790 | 105,60 | 19,00 | 7.600.000 | 14.797.010 | |
2020-02-03 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Common Stock |
C - Conversion | 378.790 | 378.790 | |||||
2020-01-31 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -509.970 | 0 | -100,00 | 15,45 | -7.879.036 | ||
2020-01-31 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -8.857 | 509.970 | -1,71 | 15,45 | -136.808 | 7.877.150 | |
2020-01-28 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -65.891 | 518.827 | -11,27 | 15,51 | -1.021.936 | 8.046.747 | |
2020-01-28 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -193.359 | 584.718 | -24,85 | 15,77 | -3.049.600 | 9.221.997 | |
2020-01-28 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -380.256 | 778.077 | -32,83 | 15,69 | -5.965.000 | 12.205.538 | |
2019-12-27 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -151.233 | 1.766.106 | -7,89 | 21,95 | -3.319.579 | 38.766.203 | |
2019-12-27 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -198.767 | 2.321.199 | -7,89 | 21,95 | -4.362.956 | 50.950.550 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -56.595 | 1.917.339 | -2,87 | 21,83 | -1.235.435 | 41.854.360 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -74.384 | 2.519.966 | -2,87 | 21,83 | -1.623.758 | 55.009.346 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -9.130 | 1.973.934 | -0,46 | 21,50 | -196.297 | 42.439.976 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -11.999 | 2.594.350 | -0,46 | 21,50 | -257.981 | 55.779.044 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -5.454 | 1.983.064 | -0,27 | 21,68 | -118.219 | 42.984.102 | |
2019-12-23 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
S - Sale | -7.168 | 2.606.349 | -0,27 | 21,68 | -155.371 | 56.494.178 | |
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Private Placement Warrants |
J - Other | -460.685 | 1.640.981 | -21,92 | ||||
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Common Stock |
J - Other | -6.087 | 20.000 | -23,33 | ||||
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Common Stock |
J - Other | -652.253 | 2.279.888 | -22,24 | ||||
2019-11-13 |
|
4 | AHCO |
AdaptHealth Corp.
Common Stock |
A - Award | 12.400.000 | 14.900.000 | 496,00 | 10,00 | 124.000.000 | 149.000.000 | |
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Series B Preferred Stock |
C - Conversion | -696.379 | 0 | -100,00 | ||||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Series B Preferred Stock |
C - Conversion | -696.379 | 0 | -100,00 | ||||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Common Stock |
P - Purchase | 700.000 | 700.000 | 11,00 | 7.700.000 | 7.700.000 | ||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Common Stock |
C - Conversion | 464.253 | 464.253 | |||||
2019-10-30 |
|
4 | CABA |
Cabaletta Bio, Inc.
Common Stock |
C - Conversion | 464.253 | 464.253 | |||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -3.184.948 | 0 | -100,00 | ||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -3.184.948 | 0 | -100,00 | ||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Common Stock |
P - Purchase | 285.714 | 285.714 | 14,00 | 3.999.996 | 3.999.996 | ||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Common Stock |
C - Conversion | 472.860 | 472.860 | |||||
2019-10-07 |
|
4 | FREQ |
Frequency Therapeutics, Inc.
Common Stock |
C - Conversion | 472.860 | 472.860 | |||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12.467.650 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12.467.650 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 166.000 | 166.000 | 15,00 | 2.490.000 | 2.490.000 | ||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 166.000 | 166.000 | 15,00 | 2.490.000 | 2.490.000 | ||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.558.456 | 1.558.456 | |||||
2019-07-24 |
|
4 | MIRM |
Mirum Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.558.456 | 1.558.456 | |||||
2019-07-01 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -590.801 | 3.159.165 | -15,75 | 2,69 | -1.589.668 | 8.500.365 | |
2019-07-01 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -108.674 | 964.101 | -10,13 | 2,69 | -292.409 | 2.594.107 | |
2019-06-26 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -1.352 | 3.749.966 | -0,04 | 4,50 | -6.086 | 16.880.472 | |
2019-06-26 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -352 | 1.072.775 | -0,03 | 4,50 | -1.585 | 4.829.097 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -40.850 | 3.751.318 | -1,08 | 4,51 | -184.189 | 16.914.318 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -10.634 | 1.073.127 | -0,98 | 4,51 | -47.948 | 4.838.622 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -50.177 | 3.792.168 | -1,31 | 4,52 | -226.925 | 17.150.080 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -13.063 | 1.083.761 | -1,19 | 4,52 | -59.077 | 4.901.309 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -269.402 | 3.842.345 | -6,55 | 4,62 | -1.243.398 | 17.733.959 | |
2019-06-25 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -70.135 | 1.096.824 | -6,01 | 4,62 | -323.701 | 5.062.281 | |
2019-06-11 |
|
4 | FIXX |
Homology Medicines, Inc.
Stock Option (Right to Buy) |
A - Award | 15.580 | 15.580 | |||||
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -71.869 | 1.166.959 | -5,80 | 6,05 | -434.750 | 7.059.168 | |
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -108.696 | 4.111.747 | -2,58 | 6,05 | -657.524 | 24.872.780 | |
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -172.800 | 1.238.828 | -12,24 | 6,16 | -1.064.016 | 7.628.083 | |
2019-05-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -261.345 | 4.220.443 | -5,83 | 6,16 | -1.609.232 | 25.987.378 | |
2019-04-15 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
P - Purchase | 533.333 | 1.158.333 | 85,33 | 22,50 | 11.999.992 | 26.062.492 | |
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series C Preferred Stock |
C - Conversion | -284.659 | 0 | -100,00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series C Preferred Stock |
C - Conversion | -284.659 | 0 | -100,00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series B Preferred Stock |
C - Conversion | -1.619.433 | 0 | -100,00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Series B Preferred Stock |
C - Conversion | -1.619.433 | 0 | -100,00 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
P - Purchase | 10.000 | 10.000 | 17,00 | 170.000 | 170.000 | ||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
P - Purchase | 10.000 | 10.000 | 17,00 | 170.000 | 170.000 | ||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
P - Purchase | 10.000 | 10.000 | 17,00 | 170.000 | 170.000 | ||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 23.333 | 156.073 | 17,58 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 23.333 | 156.073 | 17,58 | ||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 132.740 | 132.740 | |||||
2019-03-11 |
|
4 | SWAV |
ShockWave Medical, Inc.
Common Stock |
C - Conversion | 132.740 | 132.740 | |||||
2019-02-12 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.351 | 856.470 | -0,16 | 15,00 | -20.265 | 12.847.050 | |
2019-02-12 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -5.890 | 857.821 | -0,68 | 15,11 | -88.986 | 12.959.874 | |
2019-02-07 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -9.409 | 863.711 | -1,08 | 15,00 | -141.135 | 12.955.665 | |
2019-02-07 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -400 | 873.120 | -0,05 | 15,00 | -6.000 | 13.096.800 | |
2019-02-07 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -4.998 | 873.520 | -0,57 | 15,07 | -75.308 | 13.161.850 | |
2019-01-30 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -6.210 | 878.518 | -0,70 | 15,14 | -94.028 | 13.301.992 | |
2019-01-30 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -828 | 884.728 | -0,09 | 15,00 | -12.420 | 13.270.920 | |
2019-01-25 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -76.820 | 885.556 | -7,98 | 15,08 | -1.158.254 | 13.351.971 | |
2019-01-25 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -5.425 | 962.376 | -0,56 | 15,03 | -81.563 | 14.468.938 | |
2019-01-25 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -32.199 | 967.801 | -3,22 | 16,35 | -526.376 | 15.821.224 | |
2019-01-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2019-01-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2019-01-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2019-01-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-27 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-27 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-27 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-12-21 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Cash-Settled Total Return Swap |
J - Other | 1 | 1 | |||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
10.375.204 | ||||||||
2018-10-24 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common stock |
7.305.044 | ||||||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Series C Preferred Stock |
C - Conversion | -998.004 | 0 | -100,00 | ||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Series C Preferred Stock |
C - Conversion | -998.004 | 0 | -100,00 | ||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Series C Preferred Stock |
C - Conversion | -998.004 | 0 | -100,00 | ||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
P - Purchase | 104.166 | 411.244 | 33,92 | 16,00 | 1.666.656 | 6.579.904 | |
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
P - Purchase | 104.167 | 411.245 | 33,92 | 16,00 | 1.666.672 | 6.579.920 | |
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
P - Purchase | 104.167 | 411.245 | 33,92 | 16,00 | 1.666.672 | 6.579.920 | |
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
C - Conversion | 307.078 | 307.078 | |||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
C - Conversion | 307.078 | 307.078 | |||||
2018-10-01 |
|
4 | ARVN |
ARVINAS INC.
Common Stock |
C - Conversion | 307.078 | 307.078 | |||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock |
C - Conversion | -7.000.000 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200.000 | 835.843 | 31,45 | 15,00 | 3.000.000 | 12.537.645 | |
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
C - Conversion | 635.843 | 635.843 | |||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
9.719.503 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
7.411.447 | ||||||||
2018-07-23 | 3 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
6.283.058 | ||||||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1.557.292 | 0 | -100,00 | ||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1.557.292 | 0 | -100,00 | ||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 624.333 | 1.498.666 | 71,41 | 15,00 | 9.364.995 | 22.479.990 | |
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 125.667 | 1.000.000 | 14,37 | 15,00 | 1.885.005 | 15.000.000 | |
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 874.333 | 874.333 | |||||
2018-06-27 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 874.333 | 874.333 | |||||
2018-06-25 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
S - Sale | -114.034 | 952.265 | -10,69 | 5,99 | -683.315 | 5.706.162 | |
2018-06-12 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 12.700 | 12.700 | |||||
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Series C Preferred Stock |
C - Conversion | -383.538 | 0 | -100,00 | ||||
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 235.019 | 843.352 | 38,63 | 19,24 | 4.520.943 | 16.223.141 | |
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 25.000 | 608.333 | 4,29 | 20,91 | 522.748 | 12.720.182 | |
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 250.000 | 583.333 | 75,00 | 19,81 | 4.953.150 | 11.557.343 | |
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
P - Purchase | 333.333 | 333.333 | 18,00 | 5.999.994 | 5.999.994 | ||
2018-05-31 |
|
4 | KNSA |
Kiniksa Pharmaceuticals, Ltd.
Class A Common Stock |
C - Conversion | 383.538 | 383.538 | |||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17.242.766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17.242.766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17.242.766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17.242.766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17.242.766 | ||||||||
2018-05-10 | 3 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
17.242.766 | ||||||||
2018-05-10 |
|
4 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
S - Sale | -202.006 | 8.308.455 | -2,37 | 13,74 | -2.775.562 | 114.158.172 | |
2018-05-10 |
|
4 | MNK |
Mallinckrodt plc
Ordinary Shares, $0.20 par value |
S - Sale | -110.922 | 8.510.461 | -1,29 | 12,75 | -1.414.256 | 108.508.378 | |
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.854.839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.776.217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.920.342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4.391.302 | ||||||||
2018-04-04 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
J - Other | -3.913 | 26.087 | -13,04 | ||||
2018-04-04 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
J - Other | -921.848 | 6.045.652 | -13,23 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series B Preferred Stock |
C - Conversion | -6.944.444 | 0 | -100,00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series B Preferred Stock |
C - Conversion | -6.944.445 | 0 | -100,00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series A Preferred Stock |
C - Conversion | -3.521.126 | 0 | -100,00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Series A Preferred Stock |
C - Conversion | -3.521.126 | 0 | -100,00 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
P - Purchase | 625.000 | 625.000 | 16,00 | 10.000.000 | 10.000.000 | ||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
P - Purchase | 625.000 | 625.000 | 16,00 | 10.000.000 | 10.000.000 | ||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 1.319.483 | 1.988.517 | 197,22 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 1.319.484 | 1.988.518 | 197,22 | ||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 669.034 | 669.034 | |||||
2018-04-04 |
|
4 | FIXX |
Homology Medicines, Inc.
Common Stock |
C - Conversion | 669.034 | 669.034 | |||||
2018-03-29 |
|
4 | FIXX |
Homology Medicines, Inc.
Stock Option (Right to Buy) |
A - Award | 31.160 | 31.160 | |||||
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -2.233 | 305.965 | -0,72 | 29,03 | -64.824 | 8.882.164 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -5.890 | 807.257 | -0,72 | 29,03 | -170.987 | 23.434.671 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -328 | 308.198 | -0,11 | 30,00 | -9.840 | 9.245.940 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -866 | 813.147 | -0,11 | 30,00 | -25.980 | 24.394.410 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -2.748 | 308.526 | -0,88 | 30,00 | -82.440 | 9.255.780 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -7.252 | 814.013 | -0,88 | 30,00 | -217.560 | 24.420.390 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -10.802 | 311.274 | -3,35 | 31,18 | -336.806 | 9.705.523 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -28.498 | 821.265 | -3,35 | 31,18 | -888.568 | 25.607.043 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -3.617 | 322.076 | -1,11 | 29,94 | -108.293 | 9.642.955 | |
2018-03-21 |
|
4/A | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -9.544 | 849.763 | -1,11 | 29,94 | -285.747 | 25.441.904 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -8.123 | 1.113.222 | -0,72 | 29,03 | -235.811 | 32.316.835 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -1.194 | 1.121.345 | -0,11 | 30,00 | -35.820 | 33.640.350 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -10.000 | 1.122.539 | -0,88 | 30,00 | -300.000 | 33.676.170 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -39.300 | 1.132.539 | -3,35 | 31,18 | -1.225.374 | 35.312.566 | |
2018-03-08 |
|
4 | CBIO |
CATALYST BIOSCIENCES, INC.
Common Stock |
S - Sale | -13.161 | 1.171.839 | -1,11 | 29,94 | -394.040 | 35.084.860 | |
2018-02-23 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Private Placement Warrants |
P - Purchase | 4.333.333 | 4.333.333 | 1,50 | 6.500.000 | 6.500.000 | ||
2018-02-23 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Public Warrants |
P - Purchase | 833.333 | 833.333 | |||||
2018-02-23 |
|
4 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
P - Purchase | 2.500.000 | 2.500.000 | |||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2.044.307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1.510.693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2.044.307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1.510.693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2.044.307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1.510.693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2.044.307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1.510.693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2.044.307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1.510.693 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
2.044.307 | ||||||||
2018-02-15 | 3 | CBIO |
CATALYST BIOSCIENCES, INC.
Common stock |
1.510.693 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13.965.000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7.027.500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13.965.000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7.027.500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13.965.000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7.027.500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13.965.000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7.027.500 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
13.965.000 | ||||||||
2018-02-15 | 3 | DFBH |
DFB Healthcare Acquisitions Corp.
Common Stock |
7.027.500 | ||||||||
2017-12-04 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
S - Sale | -110.557 | 0 | -100,00 | 1,75 | -193.475 | ||
2017-12-04 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 110.557 | 197.424 | 127,27 | 1,75 | 193.475 | 345.492 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock |
C - Conversion | -2.668.518 | 0 | -100,00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock |
C - Conversion | -2.668.518 | 0 | -100,00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 177.500 | 468.505 | 61,00 | 17,00 | 3.017.500 | 7.964.585 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 177.500 | 468.505 | 61,00 | 17,00 | 3.017.500 | 7.964.585 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 291.005 | 291.005 | |||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 291.005 | 291.005 | |||||
2017-08-04 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 13.333 | 13.333 | |||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
2.102.698 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.374.575 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.335.456 | ||||||||
2017-08-04 | 3 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
1.311.766 | ||||||||
2017-06-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -68.000 | 1.176.685 | -5,46 | 6,25 | -425.000 | 7.354.281 | |
2017-06-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -32.447 | 1.244.685 | -2,54 | 6,59 | -213.826 | 8.202.474 | |
2017-06-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -10.000 | 1.277.132 | -0,78 | 6,74 | -67.400 | 8.607.870 | |
2017-06-09 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -17.245 | 1.287.132 | -1,32 | 6,99 | -120.543 | 8.997.053 | |
2017-06-09 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
S - Sale | -45.623 | 1.304.377 | -3,38 | 7,09 | -323.467 | 9.248.033 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -71.837 | 877.606 | -7,57 | 11,71 | -841.211 | 10.276.766 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -58.067 | 709.386 | -7,57 | 11,71 | -679.965 | 8.306.910 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -183.805 | 244.562 | -42,91 | 11,71 | -2.152.357 | 2.863.821 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -25.932 | 949.443 | -2,66 | 11,52 | -298.737 | 10.937.583 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -20.962 | 767.453 | -2,66 | 11,52 | -241.482 | 8.841.059 | |
2017-04-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -66.351 | 428.367 | -13,41 | 11,52 | -764.364 | 4.934.788 | |
2017-04-17 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -34.349 | 975.375 | -3,40 | 11,00 | -377.839 | 10.729.125 | |
2017-04-17 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -27.765 | 788.415 | -3,40 | 11,00 | -305.415 | 8.672.565 | |
2017-04-17 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -87.886 | 494.718 | -15,09 | 11,00 | -966.746 | 5.441.898 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -7.658 | 1.009.724 | -0,75 | 11,01 | -84.334 | 11.119.586 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -6.189 | 816.180 | -0,75 | 11,01 | -68.156 | 8.988.182 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -19.593 | 582.604 | -3,25 | 11,01 | -215.768 | 6.415.927 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -18.264 | 1.017.382 | -1,76 | 11,04 | -201.589 | 11.229.354 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -14.763 | 822.369 | -1,76 | 11,04 | -162.947 | 9.076.898 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -46.730 | 602.197 | -7,20 | 11,04 | -515.782 | 6.646.749 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -27.228 | 1.035.646 | -2,56 | 11,72 | -319.011 | 12.133.939 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -22.009 | 837.132 | -2,56 | 11,72 | -257.864 | 9.808.090 | |
2017-04-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -69.667 | 648.927 | -9,69 | 11,72 | -816.239 | 7.603.023 | |
2017-01-26 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -517.450 | 2.358.636 | -17,99 | 1,46 | -752.941 | 3.432.051 | |
2017-01-26 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -71.468 | 2.876.086 | -2,42 | 1,50 | -107.223 | 4.314.992 | |
2017-01-26 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -47.320 | 2.947.554 | -1,58 | 1,50 | -71.065 | 4.426.637 | |
2017-01-23 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -86.691 | 2.994.874 | -2,81 | 1,46 | -127.002 | 4.387.490 | |
2017-01-23 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -46.522 | 3.081.565 | -1,49 | 1,53 | -71.267 | 4.720.649 | |
2017-01-23 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -71.913 | 3.128.087 | -2,25 | 1,60 | -115.082 | 5.005.878 | |
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.392.550 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
2.482.450 | ||||||||
2016-12-16 | 3 | REPH |
Recro Pharma, Inc.
Common stock |
3.425.000 | ||||||||
2016-12-14 |
|
4 | IVTY |
Invuity, Inc.
Common Stock |
S - Sale | -45.568 | 1.690.498 | -2,62 | 6,01 | -273.677 | 10.152.962 | |
2016-12-14 |
|
4 | IVTY |
Invuity, Inc.
Common Stock |
S - Sale | -71.173 | 1.736.066 | -3,94 | 6,13 | -436.148 | 10.638.612 | |
2016-12-14 |
|
4 | IVTY |
Invuity, Inc.
Common Stock |
S - Sale | -68.055 | 1.807.239 | -3,63 | 6,45 | -439.084 | 11.660.125 | |
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3.750.588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3.750.588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3.750.588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3.750.588 | ||||||||
2016-11-10 | 3 | IVTY |
Invuity, Inc.
Common Stock |
3.750.588 | ||||||||
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -157.607 | 693.171 | -18,53 | 16,71 | -2.633.140 | 11.580.808 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -348.258 | 2.035.697 | -14,61 | 16,71 | -5.818.346 | 34.010.390 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -273.632 | 1.599.476 | -14,61 | 16,71 | -4.571.570 | 26.722.446 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -68.940 | 850.778 | -7,50 | 16,24 | -1.119.517 | 13.815.784 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -152.334 | 2.383.955 | -6,01 | 16,24 | -2.473.752 | 38.713.045 | |
2016-09-26 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -119.690 | 1.873.108 | -6,01 | 16,24 | -1.943.646 | 30.417.401 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -37.044 | 919.718 | -3,87 | 15,58 | -577.146 | 14.329.206 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -4.910 | 2.536.289 | -0,19 | 15,53 | -76.242 | 39.383.496 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -3.857 | 1.992.798 | -0,19 | 15,53 | -59.891 | 30.944.167 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -87.858 | 956.762 | -8,41 | 15,62 | -1.372.254 | 14.943.666 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -119.008 | 2.541.199 | -4,47 | 15,62 | -1.858.786 | 39.690.987 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -93.506 | 1.996.655 | -4,47 | 15,62 | -1.460.470 | 31.185.754 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -58.997 | 1.044.620 | -5,35 | 15,76 | -929.498 | 16.457.988 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -79.915 | 2.660.207 | -2,92 | 15,76 | -1.259.061 | 41.911.561 | |
2016-09-19 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
S - Sale | -62.791 | 2.090.161 | -2,92 | 15,76 | -989.272 | 32.930.487 | |
2016-09-14 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 12.300 | 12.300 | |||||
2016-08-01 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
S - Sale | -901.430 | 1.151.802 | -43,90 | 3,31 | -2.985.356 | 3.814.538 | |
2016-08-01 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
S - Sale | -246.439 | 314.889 | -43,90 | 3,31 | -816.157 | 1.042.849 | |
2016-08-01 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
S - Sale | -193.630 | 247.413 | -43,90 | 3,31 | -641.264 | 819.382 | |
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -99.830 | 0 | -100,00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -99.830 | 0 | -100,00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -267.998 | 0 | -100,00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -535.996 | 0 | -100,00 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
P - Purchase | 146.596 | 514.424 | 39,85 | 15,00 | 2.198.940 | 7.716.360 | |
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
P - Purchase | 253.404 | 889.230 | 39,85 | 15,00 | 3.801.060 | 13.338.450 | |
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 99.830 | 367.828 | 37,25 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 99.830 | 367.828 | 37,25 | ||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 267.998 | 267.998 | |||||
2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 535.996 | 535.996 | |||||
2016-07-21 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -102.136 | 3.000.000 | -3,29 | 6,70 | -684.311 | 20.100.000 | |
2016-07-18 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -41.425 | 3.102.136 | -1,32 | 6,87 | -284.590 | 21.311.674 | |
2016-07-18 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -31.788 | 3.143.561 | -1,00 | 7,32 | -232.688 | 23.010.867 | |
2016-07-18 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -206.090 | 3.175.349 | -6,09 | 7,70 | -1.586.893 | 24.450.187 | |
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -508.566 | 0 | -100,00 | ||||
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.186.654 | 0 | -100,00 | ||||
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 120.000 | 628.566 | 23,60 | 12,50 | 1.500.000 | 7.857.075 | |
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 280.000 | 1.466.654 | 23,60 | 12,50 | 3.500.000 | 18.333.175 | |
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 508.566 | 508.566 | |||||
2016-07-06 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.186.654 | 1.186.654 | |||||
2016-06-22 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -26.400 | 718.594 | -3,54 | 14,30 | -377.552 | 10.276.757 | |
2016-06-22 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -178.454 | 744.994 | -19,32 | 14,20 | -2.533.511 | 10.576.680 | |
2016-06-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -43.300 | 923.448 | -4,48 | 13,88 | -601.169 | 12.820.967 | |
2016-06-08 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -28.080 | 966.748 | -2,82 | 13,84 | -388.633 | 13.379.986 | |
2016-06-08 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -7.154 | 994.828 | -0,71 | 13,89 | -99.380 | 13.819.653 | |
2016-06-08 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -28.502 | 1.001.982 | -2,77 | 14,00 | -399.037 | 14.028.049 | |
2016-06-02 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -42.668 | 1.030.484 | -3,98 | 13,87 | -591.741 | 14.291.267 | |
2016-06-02 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -5 | 1.073.152 | 0,00 | 13,80 | -69 | 14.809.498 | |
2016-06-02 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -56.835 | 1.073.157 | -5,03 | 13,84 | -786.625 | 14.853.029 | |
2016-05-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -72.649 | 1.129.992 | -6,04 | 14,00 | -1.016.926 | 15.817.402 | |
2016-05-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -93.965 | 1.202.641 | -7,25 | 14,16 | -1.330.808 | 17.032.764 | |
2016-05-27 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
S - Sale | -45.967 | 1.296.606 | -3,42 | 14,25 | -655.172 | 18.480.655 | |
2016-02-23 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 11.745 | 2.746.650 | 0,43 | 3,99 | 46.843 | 10.954.464 | |
2016-02-23 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 9.228 | 2.158.084 | 0,43 | 3,99 | 36.804 | 8.607.086 | |
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
C - Conversion | -117.998 | 0 | -100,00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
C - Conversion | -117.996 | 0 | -100,00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class C Preferred Stock |
C - Conversion | -1.182.941 | 0 | -100,00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class B-1 Preferred Stock |
C - Conversion | -67.448 | 0 | -100,00 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 112.000 | 112.000 | 20,00 | 2.240.000 | 2.240.000 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 88.000 | 88.000 | 20,00 | 1.760.000 | 1.760.000 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 163.702 | 413.611 | 65,50 | 20,00 | 3.274.040 | 8.272.220 | |
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 122.793 | 1.623.089 | 8,18 | 20,00 | 2.455.860 | 32.461.780 | |
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 117.998 | 249.909 | 89,45 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 117.996 | 1.500.296 | 8,54 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 1.182.941 | 1.382.300 | 593,37 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
C - Conversion | 67.448 | 199.359 | 51,13 | ||||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
P - Purchase | 117.998 | 0 | -100,00 | 21,01 | 2.479.138 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Class D Preferred Stock |
P - Purchase | 117.996 | 0 | -100,00 | 21,01 | 2.479.096 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 131.911 | 131.911 | 18,48 | 2.437.715 | 2.437.715 | ||
2016-02-19 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
P - Purchase | 131.911 | 131.911 | 18,48 | 2.437.715 | 2.437.715 | ||
2016-02-17 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 13.872 | 2.053.232 | 0,68 | 6,25 | 86.653 | 12.825.719 | |
2016-02-17 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 28.377 | 561.328 | 5,32 | 6,25 | 177.260 | 3.506.391 | |
2016-02-17 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 22.296 | 441.043 | 5,32 | 6,25 | 139.274 | 2.755.019 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 19.725 | 2.734.905 | 0,73 | 3,92 | 77.381 | 10.729.032 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 15.499 | 2.148.856 | 0,73 | 3,92 | 60.803 | 8.429.962 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 1.157.189 | 2.715.180 | 74,27 | 3,76 | 4.349.642 | 10.205.819 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 909.221 | 2.133.357 | 74,27 | 3,76 | 3.417.580 | 8.018.862 | |
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 1.557.991 | 1.557.991 | 3,96 | 6.166.840 | 6.166.840 | ||
2016-02-16 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 1.224.136 | 1.224.136 | 3,96 | 4.845.375 | 4.845.375 | ||
2016-02-12 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | -8.385 | 8.385 | -50,00 | ||||
2016-02-12 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | -18.111 | 18.111 | -50,00 | ||||
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 504 | 2.039.360 | 0,02 | 6,19 | 3.119 | 12.620.375 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 1.030 | 532.951 | 0,19 | 6,19 | 6.374 | 3.298.114 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 810 | 418.747 | 0,19 | 6,19 | 5.013 | 2.591.374 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 32.501 | 2.038.856 | 1,62 | 6,23 | 202.556 | 12.706.762 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 66.486 | 531.921 | 14,28 | 6,23 | 414.361 | 3.315.091 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 52.239 | 417.937 | 14,28 | 6,23 | 325.569 | 2.604.709 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 24.484 | 2.006.355 | 1,24 | 5,73 | 140.271 | 11.494.608 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 50.086 | 465.435 | 12,06 | 5,73 | 286.948 | 2.666.524 | |
2016-02-11 |
|
4 | ZFGN |
ZAFGEN, INC.
Common Stock |
P - Purchase | 39.353 | 365.698 | 12,06 | 5,73 | 225.457 | 2.095.120 | |
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
4.705.436 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.049.910 | ||||||||
2016-02-11 | 3 | ZFGN |
ZAFGEN, INC.
Common Stock |
3.138.914 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
395.733 | ||||||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -854.700 | 0 | -100,00 | ||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -854.700 | 0 | -100,00 | ||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
P - Purchase | 100.000 | 954.700 | 11,70 | 16,00 | 1.600.000 | 15.275.200 | |
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 854.700 | 854.700 | |||||
2016-02-08 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 854.700 | 854.700 | |||||
2016-01-22 |
|
4 | XNPT |
XENOPORT INC
Common Stock |
P - Purchase | 346.417 | 6.667.391 | 5,48 | 4,09 | 1.418.404 | 27.299.632 | |
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12.641.948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12.641.948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12.641.948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12.641.948 | ||||||||
2016-01-22 | 3 | XNPT |
XENOPORT INC
Common Stock |
12.641.948 | ||||||||
2015-12-18 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 3.239 | 1.103.617 | 0,29 | 8,97 | 29.042 | 9.895.582 | |
2015-12-18 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 4.441 | 2.740.122 | 0,16 | 8,97 | 39.820 | 24.569.304 | |
2015-12-18 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 3.490 | 2.152.952 | 0,16 | 8,97 | 31.293 | 19.304.444 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 93.634 | 1.100.378 | 9,30 | 8,61 | 806.086 | 9.473.044 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 128.374 | 2.735.681 | 4,92 | 8,61 | 1.105.159 | 23.551.204 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 100.864 | 2.149.462 | 4,92 | 8,61 | 868.328 | 18.504.503 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29.902 | 1.006.744 | 3,06 | 8,59 | 256.864 | 8.648.132 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 40.997 | 2.607.307 | 1,60 | 8,59 | 352.172 | 22.397.289 | |
2015-12-18 |
|
4/A | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 32.211 | 2.048.598 | 1,60 | 8,59 | 276.699 | 17.597.867 | |
2015-12-17 |
|
4 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
S - Sale | -226.000 | 1.875.500 | -10,75 | 1,20 | -271.968 | 2.256.977 | |
2015-12-17 |
|
4 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
S - Sale | -116.464 | 2.101.500 | -5,25 | 1,23 | -142.831 | 2.577.280 | |
2015-12-17 |
|
4 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
S - Sale | -54.795 | 2.217.964 | -2,41 | 1,34 | -73.486 | 2.974.512 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 93.634 | 1.100.378 | 9,30 | 8,61 | 806.086 | 9.473.044 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 128.374 | 2.726.895 | 4,94 | 8,61 | 1.105.159 | 23.475.566 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 100.864 | 2.158.248 | 4,90 | 8,61 | 868.328 | 18.580.141 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29.902 | 1.006.744 | 3,06 | 8,59 | 256.864 | 8.648.132 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 32.211 | 2.598.521 | 1,26 | 8,59 | 276.699 | 22.321.815 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 40.997 | 2.057.384 | 2,03 | 8,59 | 352.172 | 17.673.340 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11.506 | 976.842 | 1,19 | 9,00 | 103.554 | 8.791.578 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 15.775 | 2.566.310 | 0,62 | 9,00 | 141.975 | 23.096.790 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 12.395 | 2.016.387 | 0,62 | 9,00 | 111.555 | 18.147.483 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 213.358 | 965.336 | 28,37 | 8,21 | 1.751.883 | 7.926.374 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 292.515 | 2.550.535 | 12,95 | 8,21 | 2.401.841 | 20.942.443 | |
2015-12-11 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 229.833 | 2.003.992 | 12,95 | 8,21 | 1.887.159 | 16.454.778 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 27.530 | 728.718 | 3,93 | 3,04 | 83.774 | 2.217.489 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 27.529 | 4.760.408 | 0,58 | 3,04 | 83.771 | 14.485.922 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 68.294 | 701.188 | 10,79 | 3,00 | 204.848 | 2.103.213 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 68.294 | 701.188 | 10,79 | 3,00 | 204.848 | 2.103.213 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 40.301 | 632.894 | 6,80 | 3,01 | 121.169 | 1.902.859 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 40.301 | 632.894 | 6,80 | 3,01 | 121.169 | 1.902.859 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 53.487 | 592.593 | 9,92 | 3,00 | 160.589 | 1.779.201 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 53.486 | 4.624.284 | 1,17 | 3,00 | 160.586 | 13.883.950 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 55.257 | 539.106 | 11,42 | 2,98 | 164.876 | 1.608.584 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 55.257 | 539.106 | 11,42 | 2,98 | 164.876 | 1.608.584 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12.882 | 483.849 | 2,74 | 3,05 | 39.273 | 1.475.110 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12.883 | 4.515.541 | 0,29 | 3,05 | 39.276 | 13.766.530 | |
2015-11-10 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 36.625 | 470.967 | 8,43 | 2,98 | 109.241 | 1.404.753 | |
2015-11-10 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 36.625 | 470.967 | 8,43 | 2,98 | 109.241 | 1.404.753 | |
2015-11-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 8.271 | 434.342 | 1,94 | 3,00 | 24.813 | 1.303.026 | |
2015-11-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 8.271 | 434.342 | 1,94 | 3,00 | 24.813 | 1.303.026 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 13.165 | 426.071 | 3,19 | 2,99 | 39.363 | 1.273.952 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 13.165 | 426.071 | 3,19 | 2,99 | 39.363 | 1.273.952 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 16.506 | 412.906 | 4,16 | 3,00 | 49.518 | 1.238.718 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 16.506 | 412.906 | 4,16 | 3,00 | 49.518 | 1.238.718 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 17.117 | 396.400 | 4,51 | 3,00 | 51.361 | 1.189.438 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 17.116 | 4.428.091 | 0,39 | 3,00 | 51.358 | 13.286.930 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12.090 | 379.283 | 3,29 | 3,00 | 36.270 | 1.137.849 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12.091 | 4.410.975 | 0,27 | 3,00 | 36.273 | 13.232.925 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 975 | 367.193 | 0,27 | 3,00 | 2.925 | 1.101.579 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 975 | 367.193 | 0,27 | 3,00 | 2.925 | 1.101.579 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 80.342 | 366.218 | 28,10 | 3,00 | 241.042 | 1.098.727 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 80.342 | 366.218 | 28,10 | 3,00 | 241.042 | 1.098.727 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 50.065 | 285.876 | 21,23 | 3,00 | 150.060 | 856.856 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 50.065 | 285.876 | 21,23 | 3,00 | 150.060 | 856.856 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 64.613 | 235.811 | 37,74 | 2,92 | 188.825 | 689.134 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 64.613 | 235.811 | 37,74 | 2,92 | 188.825 | 689.134 | |
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -160.512 | 0 | -100,00 | ||||
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -160.512 | 0 | -100,00 | ||||
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
P - Purchase | 114.488 | 275.000 | 71,33 | 12,00 | 1.373.856 | 3.300.000 | |
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
P - Purchase | 510.512 | 671.024 | 318,05 | 12,00 | 6.126.144 | 8.052.288 | |
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
C - Conversion | 160.512 | 160.512 | |||||
2015-10-14 |
|
4 | CTMX |
CytomX Therapeutics, Inc.
Common Stock |
C - Conversion | 160.512 | 160.512 | |||||
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 71.540 | 171.198 | 71,79 | 2,53 | 180.710 | 432.446 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 71.540 | 171.198 | 71,79 | 2,53 | 180.710 | 432.446 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 19.817 | 99.658 | 24,82 | 2,50 | 49.542 | 249.145 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 19.816 | 4.131.349 | 0,48 | 2,50 | 49.540 | 10.328.372 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 69.536 | 79.841 | 674,78 | 2,30 | 159.724 | 183.395 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 69.536 | 79.841 | 674,78 | 2,30 | 159.724 | 183.395 | |
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8.483.188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.451.496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.622.413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4.648.858 | ||||||||
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -83.930 | 5.348.776 | -1,54 | 1,69 | -142.018 | 9.050.664 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -106.820 | 6.807.533 | -1,54 | 1,69 | -180.750 | 11.519.027 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -59.248 | 3.294.817 | -1,77 | 1,69 | -100.254 | 5.575.160 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -34.450 | 5.432.706 | -0,63 | 1,83 | -63.044 | 9.941.852 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43.845 | 6.914.353 | -0,63 | 1,83 | -80.236 | 12.653.266 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11.081 | 3.354.065 | -0,33 | 1,82 | -20.176 | 6.107.082 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15.696 | 5.467.156 | -0,29 | 1,82 | -28.579 | 9.954.598 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -19.976 | 6.958.198 | -0,29 | 1,82 | -36.372 | 12.669.487 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -23.700 | 3.365.146 | -0,70 | 1,81 | -42.897 | 6.090.914 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -33.572 | 5.482.852 | -0,61 | 1,81 | -60.765 | 9.923.962 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -42.728 | 6.978.174 | -0,61 | 1,81 | -77.338 | 12.630.495 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -368.676 | 5.516.424 | -6,26 | 1,81 | -669.036 | 10.010.655 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -469.224 | 7.020.902 | -6,26 | 1,81 | -851.501 | 12.740.831 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -226.857 | 5.885.100 | -3,71 | 1,80 | -408.774 | 10.604.362 | |
2015-09-30 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -288.726 | 7.490.126 | -3,71 | 1,80 | -520.255 | 13.496.458 | |
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Series D Convertible Preferred Stock |
C - Conversion | -397.079 | 0 | -100,00 | ||||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Series C Convertible Preferred Stock |
C - Conversion | -771.963 | 0 | -100,00 | ||||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
P - Purchase | 49.000 | 49.000 | 22,00 | 1.078.000 | 1.078.000 | ||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
P - Purchase | 38.500 | 38.500 | 22,00 | 847.000 | 847.000 | ||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
P - Purchase | 87.500 | 1.256.542 | 7,48 | 22,00 | 1.925.000 | 27.643.924 | |
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
C - Conversion | 397.079 | 1.169.042 | 51,44 | ||||
2015-09-22 |
|
4 | RGNX |
REGENXBIO Inc.
Common Stock |
C - Conversion | 771.963 | 771.963 | |||||
2015-09-22 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -345.000 | 3.381.439 | -9,26 | 5,50 | -1.897.983 | 18.602.649 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Warrants to Purchase |
X - Other | -104.166 | 0 | -100,00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Warrants to Purchase |
X - Other | -104.166 | 0 | -100,00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -500.000 | 0 | -100,00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -500.000 | 0 | -100,00 | ||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
P - Purchase | 200.000 | 429.166 | 87,27 | 15,00 | 3.000.000 | 6.437.490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
P - Purchase | 200.000 | 429.166 | 87,27 | 15,00 | 3.000.000 | 6.437.490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
S - Sale | -83.333 | 229.166 | -26,67 | 15,00 | -1.249.995 | 3.437.490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
S - Sale | -83.333 | 229.166 | -26,67 | 15,00 | -1.249.995 | 3.437.490 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
X - Other | 104.166 | 312.499 | 50,00 | 12,00 | 1.249.992 | 3.749.988 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
X - Other | 104.166 | 312.499 | 50,00 | 12,00 | 1.249.992 | 3.749.988 | |
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
C - Conversion | 208.333 | 208.333 | |||||
2015-07-28 |
|
4 | NEOS |
Neos Therapeutics, Inc.
Common Stock |
C - Conversion | 208.333 | 208.333 | |||||
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -31.261 | 6.111.957 | -0,51 | 2,14 | -66.995 | 13.098.535 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -39.787 | 7.778.852 | -0,51 | 2,14 | -85.268 | 16.670.858 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4.048 | 6.143.218 | -0,07 | 2,13 | -8.622 | 13.085.054 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -5.152 | 7.818.639 | -0,07 | 2,13 | -10.974 | 16.653.701 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -3.245 | 6.147.266 | -0,05 | 2,12 | -6.879 | 13.032.204 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4.131 | 7.823.791 | -0,05 | 2,12 | -8.758 | 16.586.437 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -8.096 | 6.150.511 | -0,13 | 2,11 | -17.083 | 12.977.578 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -10.304 | 7.827.922 | -0,13 | 2,11 | -21.741 | 16.516.915 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55.338 | 6.158.607 | -0,89 | 2,20 | -121.921 | 13.568.643 | |
2015-07-21 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -70.431 | 7.838.226 | -0,89 | 2,20 | -155.174 | 17.269.180 | |
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4.545.518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4.545.518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4.545.518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4.545.518 | ||||||||
2015-07-13 | 3 | STRM |
STREAMLINE HEALTH SOLUTIONS INC.
Common Stock |
4.545.518 | ||||||||
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -19.598 | 6.213.945 | -0,31 | 2,07 | -40.501 | 12.841.739 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -24.943 | 7.908.657 | -0,31 | 2,07 | -51.547 | 16.344.031 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43.956 | 6.233.543 | -0,70 | 2,06 | -90.330 | 12.809.931 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55.944 | 7.933.600 | -0,70 | 2,06 | -114.965 | 16.303.548 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43.956 | 6.277.499 | -0,70 | 2,04 | -89.890 | 12.837.485 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55.944 | 7.989.544 | -0,70 | 2,04 | -114.405 | 16.338.617 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -44.000 | 6.321.455 | -0,69 | 2,06 | -90.420 | 12.990.590 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -56.000 | 8.045.488 | -0,69 | 2,06 | -115.080 | 16.533.478 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -44.000 | 6.365.455 | -0,69 | 2,04 | -89.980 | 13.017.355 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -56.000 | 8.101.488 | -0,69 | 2,04 | -114.520 | 16.567.543 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -41.650 | 6.409.455 | -0,65 | 2,10 | -87.369 | 13.445.114 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -53.009 | 8.157.488 | -0,65 | 2,10 | -111.197 | 17.111.963 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -24.108 | 6.451.105 | -0,37 | 2,09 | -50.395 | 13.485.390 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -30.684 | 8.210.497 | -0,37 | 2,09 | -64.142 | 17.163.223 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -2.244 | 6.475.213 | -0,03 | 2,08 | -4.679 | 13.500.819 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -2.856 | 8.241.181 | -0,03 | 2,08 | -5.955 | 17.182.862 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -3.476 | 6.477.457 | -0,05 | 2,08 | -7.247 | 13.505.498 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4.424 | 8.244.037 | -0,05 | 2,08 | -9.224 | 17.188.817 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15.928 | 6.480.933 | -0,25 | 2,08 | -33.130 | 13.480.341 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -20.272 | 8.248.461 | -0,25 | 2,08 | -42.166 | 17.156.799 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -67.577 | 6.496.861 | -1,03 | 2,12 | -143.371 | 13.783.740 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -86.007 | 8.268.733 | -1,03 | 2,12 | -182.472 | 17.542.944 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -16.689 | 6.564.438 | -0,25 | 2,12 | -35.362 | 13.909.388 | |
2015-07-08 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -21.240 | 8.354.740 | -0,25 | 2,12 | -45.005 | 17.702.859 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4.664 | 6.581.127 | -0,07 | 2,11 | -9.841 | 13.886.178 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -5.936 | 8.375.980 | -0,07 | 2,11 | -12.525 | 17.673.318 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -14.624 | 6.585.791 | -0,22 | 2,10 | -30.735 | 13.841.357 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18.612 | 8.381.916 | -0,22 | 2,10 | -39.117 | 17.616.273 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -136.170 | 6.600.415 | -2,02 | 2,08 | -283.887 | 13.760.545 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -173.307 | 8.400.528 | -2,02 | 2,08 | -361.310 | 17.513.421 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -69.914 | 3.388.846 | -2,02 | 2,08 | -145.757 | 7.065.066 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -82.300 | 6.736.585 | -1,21 | 2,08 | -170.962 | 13.993.908 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -104.745 | 8.573.835 | -1,21 | 2,08 | -217.587 | 17.810.427 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -42.255 | 3.458.760 | -1,21 | 2,08 | -87.776 | 7.184.882 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -21.784 | 6.818.885 | -0,32 | 2,18 | -47.406 | 14.839.258 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27.726 | 8.678.580 | -0,32 | 2,18 | -60.337 | 18.886.326 | |
2015-07-01 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11.185 | 3.501.015 | -0,32 | 2,18 | -24.341 | 7.618.909 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -79.586 | 6.840.669 | -1,15 | 2,24 | -178.098 | 15.308.049 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -101.291 | 8.706.306 | -1,15 | 2,24 | -226.669 | 19.482.972 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -33.627 | 3.512.200 | -0,95 | 2,24 | -75.251 | 7.859.601 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -51.755 | 6.920.255 | -0,74 | 2,25 | -116.490 | 15.576.110 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -65.870 | 8.807.597 | -0,74 | 2,25 | -148.260 | 19.824.139 | |
2015-07-01 |
|
4/A | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -22.405 | 3.545.827 | -0,63 | 2,25 | -50.429 | 7.980.947 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -79.586 | 6.853.826 | -1,15 | 2,24 | -178.098 | 15.337.492 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -101.291 | 8.723.052 | -1,15 | 2,24 | -226.669 | 19.520.446 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -33.627 | 3.518.297 | -0,95 | 2,24 | -75.251 | 7.873.245 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -38.598 | 6.933.412 | -0,55 | 2,25 | -86.876 | 15.605.724 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -49.124 | 8.824.343 | -0,55 | 2,25 | -110.568 | 19.861.831 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -16.308 | 3.551.924 | -0,46 | 2,25 | -36.706 | 7.994.671 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -37.919 | 6.972.010 | -0,54 | 2,25 | -85.318 | 15.687.022 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -48.260 | 8.873.467 | -0,54 | 2,25 | -108.585 | 19.965.301 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -16.021 | 3.568.232 | -0,45 | 2,25 | -36.047 | 8.028.522 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27.085 | 7.009.929 | -0,38 | 2,25 | -60.941 | 15.772.340 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -34.471 | 8.921.727 | -0,38 | 2,25 | -77.560 | 20.073.886 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11.444 | 3.584.253 | -0,32 | 2,25 | -25.749 | 8.064.569 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27.164 | 7.037.014 | -0,38 | 2,34 | -63.466 | 16.441.280 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -34.572 | 8.956.198 | -0,38 | 2,34 | -80.774 | 20.925.261 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -11.477 | 3.595.697 | -0,32 | 2,34 | -26.815 | 8.400.986 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -29.214 | 7.064.178 | -0,41 | 2,30 | -67.192 | 16.247.609 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -37.181 | 8.990.770 | -0,41 | 2,30 | -85.516 | 20.678.771 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -12.344 | 3.607.174 | -0,34 | 2,30 | -28.391 | 8.296.500 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -41.245 | 7.093.392 | -0,58 | 2,29 | -94.418 | 16.238.193 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -52.494 | 9.027.951 | -0,58 | 2,29 | -120.169 | 20.666.785 | |
2015-06-26 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -17.427 | 3.619.518 | -0,48 | 2,29 | -39.894 | 8.285.801 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -936.839 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -817.541 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -85.962 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -54.385 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | -385.962 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1.243.423 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1.085.085 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -1.401.003 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -869.667 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | -2.013.613 | 0 | -100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 77.539 | 832.216 | 10,27 | 14,00 | 1.085.546 | 11.651.024 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 67.666 | 726.242 | 10,27 | 14,00 | 947.324 | 10.167.388 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 104.795 | 1.124.740 | 10,27 | 14,00 | 1.467.130 | 15.746.360 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 324.278 | 754.677 | 75,34 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 282.984 | 658.576 | 75,34 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 29.755 | 647.152 | 4,82 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 18.825 | 402.062 | 4,91 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 133.597 | 1.019.945 | 15,07 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 430.399 | 430.399 | |||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 375.592 | 375.592 | |||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 484.944 | 617.397 | 366,13 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 301.027 | 383.237 | 366,17 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 696.993 | 886.348 | 368,09 | ||||
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -67.475 | 7.134.637 | -0,94 | 2,35 | -158.499 | 16.759.262 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -85.877 | 9.080.445 | -0,94 | 2,35 | -201.725 | 21.329.965 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -28.510 | 3.636.945 | -0,78 | 2,35 | -66.970 | 8.543.184 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -65.479 | 7.202.112 | -0,90 | 2,41 | -157.569 | 17.331.162 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -83.338 | 9.166.322 | -0,90 | 2,41 | -200.545 | 22.057.837 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -27.666 | 3.665.455 | -0,75 | 2,41 | -66.575 | 8.820.551 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -52.518 | 7.267.591 | -0,72 | 2,41 | -126.337 | 17.482.917 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -66.842 | 9.249.660 | -0,72 | 2,41 | -160.795 | 22.250.982 | |
2015-06-23 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -22.190 | 3.693.121 | -0,60 | 2,41 | -53.380 | 8.884.172 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -1.447 | 7.320.109 | -0,02 | 2,48 | -3.589 | 18.153.870 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -1.842 | 9.316.502 | -0,02 | 2,48 | -4.568 | 23.104.925 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -611 | 3.715.311 | -0,02 | 2,48 | -1.515 | 9.213.971 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -76.728 | 7.321.556 | -1,04 | 2,48 | -189.948 | 18.125.244 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -97.654 | 9.318.344 | -1,04 | 2,48 | -241.752 | 23.068.492 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -32.419 | 3.715.922 | -0,86 | 2,48 | -80.256 | 9.199.137 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -19.889 | 7.398.284 | -0,27 | 2,41 | -47.839 | 17.795.093 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -25.313 | 9.415.998 | -0,27 | 2,41 | -60.885 | 22.648.300 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -8.403 | 3.748.341 | -0,22 | 2,41 | -20.212 | 9.015.885 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -43.506 | 7.418.173 | -0,58 | 2,40 | -104.506 | 17.819.193 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -55.372 | 9.441.311 | -0,58 | 2,40 | -133.009 | 22.678.973 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18.382 | 3.756.744 | -0,49 | 2,40 | -44.155 | 9.024.075 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -35.915 | 7.461.679 | -0,48 | 2,40 | -86.322 | 17.934.145 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -45.710 | 9.496.683 | -0,48 | 2,40 | -109.864 | 22.825.278 | |
2015-06-18 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15.175 | 3.775.126 | -0,40 | 2,40 | -36.473 | 9.073.515 | |
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486.233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536.475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593.380 | ||||||||
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -22.973 | 3.790.301 | -0,60 | 2,40 | -55.144 | 9.098.239 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -5.267 | 3.813.274 | -0,14 | 2,40 | -12.641 | 9.151.858 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -1.568 | 3.818.541 | -0,04 | 2,40 | -3.771 | 9.183.591 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -54.370 | 7.497.594 | -0,72 | 2,40 | -130.510 | 17.997.225 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -69.198 | 9.542.393 | -0,72 | 2,40 | -166.103 | 22.905.560 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -12.467 | 7.551.964 | -0,16 | 2,40 | -29.921 | 18.124.714 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -15.866 | 9.611.591 | -0,16 | 2,40 | -38.078 | 23.067.818 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -3.710 | 7.564.431 | -0,05 | 2,40 | -8.923 | 18.192.457 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -4.722 | 9.627.457 | -0,05 | 2,40 | -11.356 | 23.154.034 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -44.010 | 7.568.141 | -0,58 | 2,43 | -106.874 | 18.378.474 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -56.012 | 9.632.179 | -0,58 | 2,43 | -136.020 | 23.390.783 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18.551 | 7.612.151 | -0,24 | 2,42 | -44.986 | 18.459.466 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18.551 | 7.612.151 | -0,24 | 2,42 | -44.986 | 18.459.466 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -23.611 | 9.688.191 | -0,24 | 2,42 | -57.257 | 23.493.863 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -23.611 | 9.688.191 | -0,24 | 2,42 | -57.257 | 23.493.863 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -18.595 | 3.820.109 | -0,48 | 2,43 | -45.156 | 9.276.753 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -7.838 | 3.838.704 | -0,20 | 2,42 | -19.007 | 9.308.857 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -7.838 | 3.838.704 | -0,20 | 2,42 | -19.007 | 9.308.857 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -67.627 | 7.649.253 | -0,88 | 2,47 | -166.782 | 18.864.588 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -86.071 | 9.735.413 | -0,88 | 2,47 | -212.268 | 24.009.476 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -58.251 | 7.716.880 | -0,75 | 2,48 | -144.445 | 19.135.547 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -74.137 | 9.821.484 | -0,75 | 2,48 | -183.838 | 24.354.334 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -28.574 | 3.854.380 | -0,74 | 2,47 | -70.469 | 9.505.672 | |
2015-06-15 |
|
4 | ATRS |
ANTARES PHARMA, INC.
Common Stock |
S - Sale | -24.612 | 3.882.954 | -0,63 | 2,48 | -61.030 | 9.628.561 | |
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.536.135 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
6.558.316 | ||||||||
2015-05-18 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
7.042.177 | ||||||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -2.234.137 | 0 | -100,00 | ||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -2.234.137 | 0 | -100,00 | ||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
P - Purchase | 25.000 | 255.764 | 10,83 | 14,00 | 350.000 | 3.580.696 | |
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
P - Purchase | 25.000 | 255.764 | 10,83 | 14,00 | 350.000 | 3.580.696 | |
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 230.764 | 230.764 | |||||
2015-05-13 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 230.764 | 230.764 | |||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
29.353.449 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
31.473.939 | ||||||||
2015-05-13 | 3 | ATRS |
ANTARES PHARMA, INC.
Common stock |
25.485.884 | ||||||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -973.379 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -849.426 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -1.182.943 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -953.286 | 0 | -100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | -490.069 | 0 | -100,00 | ||||
2015-04-09 |
|
4 | AXGN |
AxoGen, Inc.
Common Stock |
S - Sale | -144.385 | 3.726.439 | -3,73 | 3,25 | -469.251 | 12.110.927 | |
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Series E Preferred Stock |
C - Conversion | -34.205 | 0 | -100,00 | ||||
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Series E Preferred Stock |
C - Conversion | -34.205 | 0 | -100,00 | ||||
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
P - Purchase | 558.440 | 823.529 | 210,66 | 8,50 | 4.746.740 | 6.999.996 | |
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
P - Purchase | 179.115 | 444.204 | 67,57 | 8,50 | 1.522.478 | 3.775.734 | |
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
C - Conversion | 265.089 | 265.089 | |||||
2015-03-25 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares |
C - Conversion | 265.089 | 265.089 | |||||
2015-03-09 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 28.716 | 1.342.573 | 2,19 | 9,52 | 273.376 | 12.781.295 | |
2015-03-09 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1.387 | 600.544 | 0,23 | 9,52 | 13.204 | 5.717.179 | |
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Series F Preferred Stock |
C - Conversion | -1.000.000 | 0 | -100,00 | ||||
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
P - Purchase | 48.388 | 48.388 | 16,00 | 774.208 | 774.208 | ||
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
P - Purchase | 39.112 | 39.112 | 16,00 | 625.792 | 625.792 | ||
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
P - Purchase | 87.500 | 254.166 | 52,50 | 16,00 | 1.400.000 | 4.066.656 | |
2015-02-19 |
|
4 | NVTA |
Invitae Corp
Common Stock |
C - Conversion | 166.666 | 166.666 | |||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7.741.648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7.741.648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7.741.648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7.741.648 | ||||||||
2015-02-10 | 3 | AXGN |
AxoGen, Inc.
Common Stock |
7.741.648 | ||||||||
2015-02-02 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
U - Other | -3.469.974 | 0 | -100,00 | ||||
2015-02-02 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
U - Other | -2.797.408 | 0 | -100,00 | ||||
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 192.240 | 973.379 | 24,61 | 56,50 | 10.861.560 | 54.995.914 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 167.760 | 849.426 | 24,61 | 56,50 | 9.478.440 | 47.992.569 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 566.825 | 1.182.943 | 92,00 | 56,50 | 32.025.612 | 66.836.280 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 458.175 | 953.286 | 92,54 | 56,50 | 25.886.888 | 53.860.659 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 115.000 | 490.069 | 30,66 | 56,50 | 6.497.500 | 27.688.898 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 420.280 | 1.804.903 | 30,35 | 20,45 | 8.594.726 | 36.910.266 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 339.720 | 1.459.685 | 30,33 | 20,45 | 6.947.274 | 29.850.558 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 132.720 | 1.384.623 | 10,60 | 19,84 | 2.632.501 | 27.463.997 | |
2015-01-16 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 107.280 | 1.119.965 | 10,59 | 19,84 | 2.127.899 | 22.214.506 | |
2015-01-05 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
S - Sale | -1.443.200 | 0 | -100,00 | 1,65 | -2.381.280 | ||
2015-01-05 |
|
4 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
P - Purchase | 1.443.200 | 3.200.000 | 82,15 | 1,65 | 2.381.280 | 5.280.000 | |
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.588.361 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
4.485.476 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.252.554 | ||||||||
2014-12-24 | 3 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
5.562.474 | ||||||||
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 20.580 | 1.674.781 | 1,24 | 14,48 | 297.998 | 24.250.829 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 16.434 | 1.346.715 | 1,24 | 14,48 | 237.964 | 19.500.433 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13.900 | 1.654.201 | 0,85 | 14,30 | 198.770 | 23.655.074 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11.100 | 1.330.281 | 0,84 | 14,30 | 158.730 | 19.023.018 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11.120 | 1.640.301 | 0,68 | 14,33 | 159.350 | 23.505.513 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 8.880 | 1.319.181 | 0,68 | 14,33 | 127.250 | 18.903.864 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13.900 | 1.629.181 | 0,86 | 14,50 | 201.550 | 23.623.124 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11.100 | 1.310.301 | 0,85 | 14,50 | 160.950 | 18.999.364 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 16.680 | 1.615.281 | 1,04 | 14,48 | 241.526 | 23.389.269 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13.320 | 1.299.201 | 1,04 | 14,48 | 192.874 | 18.812.430 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 13.900 | 1.598.601 | 0,88 | 14,23 | 197.797 | 22.748.092 | |
2014-12-24 |
|
4 | VNDA |
Vanda Pharmaceuticals Inc.
Common Stock |
P - Purchase | 11.100 | 1.285.881 | 0,87 | 14,23 | 157.953 | 18.298.087 | |
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.324.172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.444.214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.565.221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.630.769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3.730.242 | ||||||||
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -55.035 | 800.794 | -6,43 | 11,50 | -632.902 | 9.209.131 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -48.027 | 698.822 | -6,43 | 11,50 | -552.310 | 8.036.453 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -18.903 | 275.046 | -6,43 | 11,50 | -217.384 | 3.163.029 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3.785 | 855.829 | -0,44 | 11,54 | -43.679 | 9.876.267 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3.303 | 746.849 | -0,44 | 11,54 | -38.117 | 8.618.637 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -14.199 | 293.949 | -4,61 | 11,55 | -163.998 | 3.395.111 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -41.339 | 859.614 | -4,59 | 11,55 | -477.465 | 9.928.542 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -36.074 | 750.152 | -4,59 | 11,55 | -416.655 | 8.664.256 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -1.300 | 308.148 | -0,42 | 11,54 | -15.002 | 3.556.028 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -45.124 | 900.953 | -4,77 | 11,00 | -496.364 | 9.910.483 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -39.377 | 786.226 | -4,77 | 11,00 | -433.147 | 8.648.486 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -15.499 | 309.448 | -4,77 | 11,00 | -170.489 | 3.403.928 | |
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -30.100 | 0 | -100,00 | 9,33 | -280.833 | ||
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3.500 | 30.100 | -10,42 | 9,27 | -32.445 | 279.027 | |
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -180.564 | 33.600 | -84,31 | 9,00 | -1.625.076 | 302.400 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Purchase Right |
J - Other | -838.067 | 0 | -100,00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Purchase Right |
J - Other | -1.049.472 | 0 | -100,00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Purchase Right |
J - Other | -4.907.601 | 0 | -100,00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -1.047.584 | 0 | -100,00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -1.311.840 | 0 | -100,00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -6.134.501 | 0 | -100,00 | ||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 45 | 170.371 | 0,03 | 10,00 | 450 | 1.703.710 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 55 | 208.345 | 0,03 | 10,00 | 550 | 2.083.450 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 272 | 170.326 | 0,16 | 10,00 | 2.720 | 1.703.260 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 328 | 208.290 | 0,16 | 10,00 | 3.280 | 2.082.900 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 12.819 | 170.054 | 8,15 | 10,00 | 128.190 | 1.700.540 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 15.417 | 207.962 | 8,01 | 10,00 | 154.170 | 2.079.620 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 5.801 | 157.235 | 3,83 | 10,00 | 58.010 | 1.572.350 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 6.976 | 192.545 | 3,76 | 10,00 | 69.760 | 1.925.450 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 81.949 | 151.434 | 117,94 | 10,00 | 819.490 | 1.514.340 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 98.556 | 185.569 | 113,27 | 10,00 | 985.560 | 1.855.690 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
P - Purchase | 469.495 | 876.391 | 115,38 | 10,00 | 4.694.950 | 8.763.910 | |
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
C - Conversion | 69.485 | 69.485 | |||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
C - Conversion | 87.013 | 87.013 | |||||
2014-10-27 |
|
4 | PRTO |
PROTEON THERAPEUTICS INC
Common Stock |
C - Conversion | 406.896 | 406.896 | |||||
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -51.449 | 214.164 | -19,37 | 10,01 | -515.004 | 2.143.782 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -14.464 | 946.077 | -1,51 | 11,02 | -159.393 | 10.425.769 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -12.622 | 825.603 | -1,51 | 11,02 | -139.094 | 9.098.145 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -4.061 | 265.613 | -1,51 | 11,02 | -44.752 | 2.927.055 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -4.968 | 324.947 | -1,51 | 11,02 | -54.747 | 3.580.916 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -246 | 960.541 | -0,03 | 12,00 | -2.952 | 11.528.413 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -215 | 838.225 | -0,03 | 12,00 | -2.580 | 10.060.376 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -69 | 269.674 | -0,03 | 12,00 | -828 | 3.236.627 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -84 | 330 | -20,29 | 12,00 | -1.008 | 3.960 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -11.855 | 960.787 | -1,22 | 12,14 | -143.860 | 11.659.150 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -10.345 | 838.440 | -1,22 | 12,14 | -125.537 | 10.174.469 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -3.328 | 269.743 | -1,22 | 12,14 | -40.385 | 3.273.331 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | -4.072 | 329.999 | -1,22 | 12,14 | -49.414 | 4.004.538 | |
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 0 | 1.974.921,00 | |||||
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 0 | 1.599.314,00 | |||||
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 2.528.763,00 | ||||||
2014-10-01 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 2.048.365,00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 603.102,00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 743.108,00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 5.960.963,00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 7.357.516,00 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 4.852.505,67 | ||||||
2014-09-25 |
|
4 | AUXL |
AUXILIUM PHARMACEUTICALS INC
1.50% Convertible Senior Notes due 2018 |
S - Sale | 5.988.054,33 | ||||||
2014-08-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1.731 | 1.251.903 | 0,14 | 21,05 | 36.438 | 26.352.558 | |
2014-08-11 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1.400 | 1.012.685 | 0,14 | 21,05 | 29.470 | 21.317.019 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -222.839 | 0 | -100,00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -279.051 | 0 | -100,00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 77.256 | 296.125 | 35,30 | 13,05 | 1.008.191 | 3.864.431 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 218.869 | 218.869 | 13,00 | 2.845.297 | 2.845.297 | ||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 62.400 | 239.300 | 35,27 | 13,05 | 814.320 | 3.122.865 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 176.900 | 176.900 | 13,00 | 2.299.700 | 2.299.700 | ||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 246.631 | 469.470 | 110,68 | 13,00 | 3.206.203 | 6.103.110 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 307.600 | 586.651 | 110,23 | 13,00 | 3.998.800 | 7.626.463 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 222.839 | 222.839 | |||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 279.051 | 279.051 | |||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Series B Preferred Stock |
C - Conversion | -531.208 | 0 | -100,00 | ||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Series B Preferred Stock |
C - Conversion | -147.410 | 0 | -100,00 | ||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Series B Preferred Stock |
C - Conversion | -184.594 | 0 | -100,00 | ||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 31.650 | 627.267 | 5,31 | 24,57 | 777.640 | 15.411.950 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 49.981 | 595.617 | 9,16 | 26,35 | 1.316.999 | 15.694.508 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 27.600 | 545.636 | 5,33 | 26,14 | 721.464 | 14.262.925 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 12.400 | 518.036 | 2,45 | 27,54 | 341.496 | 14.266.711 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 219.864 | 505.636 | 76,94 | 26,42 | 5.808.807 | 13.358.903 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 18.700 | 285.772 | 7,00 | 25,79 | 482.273 | 7.370.060 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 9.800 | 267.072 | 3,81 | 25,52 | 250.096 | 6.815.677 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 201.972 | 257.272 | 365,23 | 25,41 | 5.132.109 | 6.537.282 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 55.300 | 55.300 | 17,00 | 940.100 | 940.100 | ||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 25.600 | 507.200 | 5,32 | 24,57 | 628.992 | 12.461.904 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 40.400 | 481.600 | 9,16 | 26,35 | 1.064.540 | 12.690.160 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 22.400 | 441.200 | 5,35 | 26,14 | 585.536 | 11.532.968 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 10.100 | 418.800 | 2,47 | 27,54 | 278.154 | 11.533.752 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 177.700 | 408.700 | 76,93 | 26,42 | 4.694.834 | 10.797.854 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 15.100 | 231.000 | 6,99 | 25,79 | 389.429 | 5.957.490 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 7.900 | 215.900 | 3,80 | 25,52 | 201.608 | 5.509.768 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 163.300 | 208.000 | 365,32 | 25,41 | 4.149.453 | 5.285.280 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 44.700 | 44.700 | 17,00 | 759.900 | 759.900 | ||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 123.077 | 654.285 | 23,17 | 17,00 | 2.092.309 | 11.122.845 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 34.223 | 181.633 | 23,22 | 17,00 | 581.791 | 3.087.761 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
P - Purchase | 42.700 | 227.294 | 23,13 | 17,00 | 725.900 | 3.863.998 | |
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
C - Conversion | 531.208 | 531.208 | |||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
C - Conversion | 147.410 | 147.410 | |||||
2014-08-05 |
|
4 | AAVL |
Avalanche Biotechnologies, Inc.
Common Stock |
C - Conversion | 184.594 | 184.594 | |||||
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 2.085 | 1.250.172 | 0,17 | 20,99 | 43.764 | 26.241.110 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 1.685 | 1.011.285 | 0,17 | 20,99 | 35.368 | 21.226.872 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 78.853 | 1.248.087 | 6,74 | 20,75 | 1.636.200 | 25.897.805 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 7.122 | 1.169.234 | 0,61 | 20,40 | 145.289 | 23.852.374 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 63.738 | 1.009.600 | 6,74 | 20,75 | 1.322.564 | 20.949.200 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 5.757 | 945.862 | 0,61 | 20,40 | 117.443 | 19.295.585 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 13.272 | 1.162.112 | 1,16 | 19,40 | 257.477 | 22.544.973 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 80.904 | 1.148.840 | 7,58 | 19,04 | 1.540.412 | 21.873.914 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 10.728 | 940.105 | 1,15 | 19,40 | 208.123 | 18.238.037 | |
2014-08-05 |
|
4 | EHTH |
eHealth, Inc.
Common Stock |
P - Purchase | 65.396 | 929.377 | 7,57 | 19,04 | 1.245.140 | 17.695.338 | |
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.795.898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.999.853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.795.898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.999.853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.795.898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.999.853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.795.898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.999.853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.795.898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.999.853 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.795.898 | ||||||||
2014-08-05 | 3 | EHTH |
eHealth, Inc.
Common stock |
2.999.853 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.064.790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.737.356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.064.790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.737.356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.064.790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.737.356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.064.790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.737.356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.064.790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.737.356 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.064.790 | ||||||||
2014-06-10 | 3 | AUXL |
AUXILIUM PHARMACEUTICALS INC
Common Stock |
9.737.356 | ||||||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -253.384 | 0 | -100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -221.118 | 0 | -100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -71.333 | 0 | -100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -86.834 | 0 | -100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 75.480 | 261.143 | 40,65 | 11,97 | 903.126 | 3.124.602 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 94.520 | 324.524 | 41,09 | 11,97 | 1.130.941 | 3.882.962 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 19.980 | 185.663 | 12,06 | 12,29 | 245.468 | 2.281.000 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 25.020 | 230.004 | 12,21 | 12,29 | 307.388 | 2.825.760 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 340.425 | 593.809 | 134,35 | 12,00 | 4.085.100 | 7.125.708 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 297.075 | 518.193 | 134,35 | 12,00 | 3.564.900 | 6.218.316 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 94.350 | 165.683 | 132,27 | 12,00 | 1.132.200 | 1.988.196 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 118.150 | 204.984 | 136,06 | 12,00 | 1.417.800 | 2.459.808 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 253.384 | 253.384 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 221.118 | 221.118 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 71.333 | 71.333 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 86.834 | 86.834 | |||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -2.323.086 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -2.027.262 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -654.002 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | -796.114 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 280.350 | 796.591 | 54,31 | 12,00 | 3.364.200 | 9.559.092 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 244.650 | 695.152 | 54,31 | 12,00 | 2.935.800 | 8.341.824 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 78.400 | 223.733 | 53,95 | 12,00 | 940.800 | 2.684.796 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 96.600 | 273.514 | 54,60 | 12,00 | 1.159.200 | 3.282.168 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 516.241 | 796.591 | 184,14 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 450.502 | 695.152 | 184,14 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 145.333 | 223.733 | 185,37 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 176.914 | 273.514 | 183,14 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -572.142 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -499.285 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -161.071 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -196.071 | 0 | -100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 400.500 | 972.642 | 70,00 | 15,00 | 6.007.500 | 14.589.630 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 349.500 | 848.785 | 70,00 | 15,00 | 5.242.500 | 12.731.775 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 112.000 | 273.071 | 69,53 | 15,00 | 1.680.000 | 4.096.065 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 138.000 | 334.071 | 70,38 | 15,00 | 2.070.000 | 5.011.065 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 572.142 | 972.642 | 142,86 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 499.285 | 848.785 | 142,86 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 161.071 | 273.071 | 143,81 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 196.071 | 334.071 | 142,08 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -187.149 | 0 | -100,00 | 0,38 | -70.817 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -116.172 | 0 | -100,00 | 0,38 | -43.959 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -39.249 | 0 | -100,00 | 0,38 | -14.852 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock Warrants (right to buy) |
S - Sale | -21.414 | 0 | -100,00 | 0,38 | -8.103 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -9.258 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -5.748 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -1.938 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -1.056 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -19.620 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -12.179 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -4.114 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -2.243 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -21.213 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -13.168 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4.448 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -2.426 | 0 | -100,00 | ||||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -14.005.557 | 0 | -100,00 | 0,06 | -785.712 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 2.830.978 | 14.005.557 | 25,33 | 0,35 | 990.842 | 4.901.945 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 7.323.275 | 11.174.579 | 190,15 | 0,30 | 2.196.982 | 3.352.374 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 3.714.455 | 3.851.304 | 2.714,27 | 0,74 | 2.733.839 | 2.834.560 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -8.694.231 | 0 | -100,00 | 0,06 | -487.746 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 1.757.664 | 8.694.231 | 25,34 | 0,35 | 615.182 | 3.042.981 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 4.545.880 | 6.936.567 | 190,15 | 0,30 | 1.363.764 | 2.080.970 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 2.305.753 | 2.390.687 | 2.714,76 | 0,74 | 1.697.034 | 1.759.546 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -2.974.566 | 0 | -100,00 | 0,06 | -166.873 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 592.613 | 2.974.566 | 24,88 | 0,35 | 207.415 | 1.041.098 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 1.535.573 | 2.381.953 | 181,43 | 0,30 | 460.672 | 714.586 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 778.856 | 846.380 | 1.153,45 | 0,74 | 573.238 | 622.936 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -1.619.176 | 0 | -100,00 | 0,06 | -90.836 | ||
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 322.911 | 1.619.176 | 24,91 | 0,35 | 113.019 | 566.712 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 837.215 | 1.296.265 | 182,38 | 0,30 | 251.164 | 388.880 | |
2013-07-18 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
C - Conversion | 424.798 | 459.050 | 1.240,21 | 0,74 | 312.651 | 337.861 | |
2013-07-17 | 3 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
1.756.800 | ||||||||
2013-07-17 | 3 | CASM |
CAS MEDICAL SYSTEMS INC
Common Stock |
1.443.200 | ||||||||
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 3.086 | 9.258 | 50,00 | 100,00 | 308.600 | 925.800 | |
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1.916 | 5.748 | 50,00 | 100,00 | 191.600 | 574.800 | |
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 646 | 1.938 | 50,00 | 100,00 | 64.600 | 193.800 | |
2013-01-15 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 352 | 1.056 | 50,00 | 100,00 | 35.200 | 105.600 | |
2012-12-20 | 3 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
514.128 | ||||||||
2012-12-20 | 3 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
603.464 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
2.422.121 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
3.223.783 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
70.820 | ||||||||
2012-12-14 | 3 | NXTM |
NxStage Medical, Inc.
Common Stock |
83.137 | ||||||||
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1.543 | 6.172 | 33,33 | 100,00 | 154.300 | 617.200 | |
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 958 | 3.832 | 33,33 | 100,00 | 95.800 | 383.200 | |
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 323 | 1.292 | 33,33 | 100,00 | 32.300 | 129.200 | |
2012-11-16 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 176 | 704 | 33,33 | 100,00 | 17.600 | 70.400 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -3.510 | 0 | -100,00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -2.179 | 0 | -100,00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -736 | 0 | -100,00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -401 | 0 | -100,00 | ||||
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 3.510 | 19.620 | 21,79 | 100,00 | 351.000 | 1.962.000 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 2.179 | 12.179 | 21,79 | 100,00 | 217.900 | 1.217.900 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 736 | 4.114 | 21,79 | 100,00 | 73.600 | 411.400 | |
2012-10-10 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 401 | 2.243 | 21,77 | 100,00 | 40.100 | 224.300 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 3.086 | 4.629 | 200,00 | 100,00 | 308.600 | 462.900 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1.916 | 2.874 | 200,00 | 100,00 | 191.600 | 287.400 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 646 | 969 | 200,00 | 100,00 | 64.600 | 96.900 | |
2012-08-21 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 352 | 528 | 200,00 | 100,00 | 35.200 | 52.800 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -228.392 | 136.849 | -62,53 | 1,22 | -278.638 | 166.956 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -141.750 | 84.934 | -62,53 | 1,22 | -172.935 | 103.619 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -112.693 | 67.524 | -62,53 | 1,22 | -137.485 | 82.379 | |
2012-07-09 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -57.165 | 34.252 | -62,53 | 1,22 | -69.741 | 41.787 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 1.543 | 1.543 | 100,00 | 154.300 | 154.300 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 958 | 958 | 100,00 | 95.800 | 95.800 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 323 | 323 | 100,00 | 32.300 | 32.300 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
A - Award | 176 | 176 | 100,00 | 17.600 | 17.600 | ||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -283.180 | 299.811 | -48,57 | 1,33 | -376.629 | 398.749 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -175.782 | 186.037 | -48,58 | 1,33 | -233.790 | 247.429 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -59.388 | 252.561 | -19,04 | 1,33 | -78.986 | 335.906 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -32.402 | 125.150 | -20,57 | 1,33 | -43.095 | 166.450 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -85.623 | 582.991 | -12,81 | 1,20 | -102.748 | 699.589 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -53.150 | 361.819 | -12,81 | 1,20 | -63.780 | 434.183 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -17.957 | 311.949 | -5,44 | 1,20 | -21.548 | 374.339 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -9.797 | 157.552 | -5,85 | 1,20 | -11.756 | 189.062 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -3.472 | 1 | -99,97 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -2.155 | 1 | -99,95 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -728 | 1 | -99,86 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -397 | 1 | -99,75 | ||||
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 3.472 | 16.110 | 27,47 | 100,00 | 347.200 | 1.611.000 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 2.155 | 10.000 | 27,47 | 100,00 | 215.500 | 1.000.000 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 728 | 3.378 | 27,47 | 100,00 | 72.800 | 337.800 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 397 | 1.842 | 27,47 | 100,00 | 39.700 | 184.200 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -82.321 | 668.614 | -10,96 | 1,14 | -93.846 | 762.220 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -51.091 | 414.969 | -10,96 | 1,14 | -58.244 | 473.065 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -40.619 | 329.906 | -10,96 | 1,14 | -46.306 | 376.093 | |
2012-07-03 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -20.604 | 167.349 | -10,96 | 1,14 | -23.489 | 190.778 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -92.964 | 750.935 | -11,02 | 1,07 | -99.471 | 803.500 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -57.697 | 466.060 | -11,02 | 1,07 | -61.736 | 498.684 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -45.871 | 370.525 | -11,02 | 1,07 | -49.082 | 396.462 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -23.268 | 187.953 | -11,02 | 1,07 | -24.897 | 201.110 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -49.170 | 843.899 | -5,51 | 1,00 | -49.170 | 843.899 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -30.517 | 523.757 | -5,51 | 1,00 | -30.517 | 523.757 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -24.262 | 416.396 | -5,51 | 1,00 | -24.262 | 416.396 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -12.307 | 211.221 | -5,51 | 1,00 | -12.307 | 211.221 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -26.357 | 893.069 | -2,87 | 0,98 | -25.830 | 875.208 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -16.358 | 554.274 | -2,87 | 0,98 | -16.031 | 543.189 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -13.005 | 440.658 | -2,87 | 0,98 | -12.745 | 431.845 | |
2012-06-28 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -6.597 | 223.528 | -2,87 | 0,98 | -6.465 | 219.057 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -27.500 | 919.426 | -2,90 | 0,98 | -26.950 | 901.037 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -70.184 | 946.926 | -6,90 | 0,99 | -69.482 | 937.457 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -17.123 | 570.632 | -2,91 | 0,98 | -16.781 | 559.219 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -43.600 | 587.755 | -6,91 | 0,99 | -43.164 | 581.877 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -11.900 | 453.663 | -2,56 | 0,98 | -11.662 | 444.590 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -30.400 | 465.563 | -6,13 | 0,99 | -30.096 | 460.907 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -8.577 | 230.125 | -3,59 | 0,98 | -8.405 | 225.522 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -21.816 | 238.702 | -8,37 | 0,99 | -21.598 | 236.315 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -3.472 | 1 | -99,97 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -2.155 | 1 | -99,95 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -728 | 1 | -99,86 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Right to acquire Series A-2 Convertible Preferred Stock |
C - Conversion | -397 | 1 | -99,75 | ||||
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 3.472 | 12.638 | 37,88 | 100,00 | 347.200 | 1.263.800 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 2.155 | 7.845 | 37,87 | 100,00 | 215.500 | 784.500 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 728 | 2.650 | 37,88 | 100,00 | 72.800 | 265.000 | |
2012-05-07 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | 397 | 1.445 | 37,88 | 100,00 | 39.700 | 144.500 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -48.600 | 1.017.110 | -4,56 | 1,05 | -51.030 | 1.067.966 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -30.226 | 631.355 | -4,57 | 1,05 | -31.737 | 662.923 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -21.074 | 495.963 | -4,08 | 1,05 | -22.128 | 520.761 | |
2012-03-23 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -15.100 | 260.518 | -5,48 | 1,05 | -15.855 | 273.544 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -15.025 | 1.065.710 | -1,39 | 1,01 | -15.175 | 1.076.367 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -9.326 | 661.581 | -1,39 | 1,01 | -9.419 | 668.197 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -7.290 | 517.037 | -1,39 | 1,01 | -7.363 | 522.207 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -3.885 | 275.618 | -1,39 | 1,01 | -3.924 | 278.374 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -7.824 | 1.080.735 | -0,72 | 1,04 | -8.137 | 1.123.964 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -4.857 | 670.907 | -0,72 | 1,04 | -5.051 | 697.743 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -3.796 | 524.327 | -0,72 | 1,04 | -3.948 | 545.300 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -2.023 | 279.503 | -0,72 | 1,04 | -2.104 | 290.683 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -52.094 | 1.088.559 | -4,57 | 1,11 | -57.824 | 1.208.300 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -32.339 | 675.764 | -4,57 | 1,11 | -35.896 | 750.098 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -25.275 | 528.123 | -4,57 | 1,11 | -28.055 | 586.217 | |
2012-03-14 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -13.472 | 281.526 | -4,57 | 1,11 | -14.954 | 312.494 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -64.706 | 1.140.653 | -5,37 | 1,20 | -77.647 | 1.368.784 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -40.167 | 708.103 | -5,37 | 1,20 | -48.200 | 849.724 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -31.393 | 553.398 | -5,37 | 1,20 | -37.672 | 664.078 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -16.734 | 294.998 | -5,37 | 1,20 | -20.081 | 353.998 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -23.261 | 1.205.359 | -1,89 | 1,04 | -24.191 | 1.253.573 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -14.439 | 748.270 | -1,89 | 1,04 | -15.017 | 778.201 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -11.285 | 584.791 | -1,89 | 1,04 | -11.736 | 608.183 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -6.015 | 311.732 | -1,89 | 1,04 | -6.256 | 324.201 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -8.881 | 1.228.620 | -0,72 | 0,99 | -8.792 | 1.216.334 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -5.513 | 762.709 | -0,72 | 0,99 | -5.458 | 755.082 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -4.310 | 596.076 | -0,72 | 0,99 | -4.267 | 590.115 | |
2012-03-12 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -2.296 | 317.747 | -0,72 | 0,99 | -2.273 | 314.570 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -10.600 | 1.237.501 | -0,85 | 0,98 | -10.388 | 1.212.751 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -6.536 | 768.222 | -0,84 | 0,98 | -6.405 | 752.858 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -4.564 | 600.386 | -0,75 | 0,98 | -4.473 | 588.378 | |
2012-02-08 |
|
4 | TLON.OB |
Talon Therapeutics, Inc.
Common Stock |
S - Sale | -3.300 | 320.043 | -1,02 | 0,98 | -3.234 | 313.642 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 301.424 | 3.204.167 | 10,38 | 8,00 | 2.411.392 | 25.633.336 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 229.252 | 2.279.997 | 11,18 | 8,00 | 1.834.016 | 18.239.976 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 72.800 | 762.700 | 10,55 | 8,00 | 582.400 | 6.101.600 | |
2011-06-07 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 46.524 | 470.425 | 10,98 | 8,00 | 372.192 | 3.763.400 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -11.557 | 781.833 | -1,46 | 0,51 | -5.894 | 398.735 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -6.443 | 435.887 | -1,46 | 0,51 | -3.286 | 222.302 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -8.925 | 793.390 | -1,11 | 0,50 | -4.462 | 396.695 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -4.975 | 442.330 | -1,11 | 0,50 | -2.488 | 221.165 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -192.615 | 802.315 | -19,36 | 0,51 | -98.234 | 409.181 | |
2010-12-14 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -107.385 | 447.305 | -19,36 | 0,51 | -54.766 | 228.126 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -20.995 | 994.930 | -2,07 | 0,58 | -12.177 | 577.059 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -11.705 | 554.690 | -2,07 | 0,58 | -6.789 | 321.720 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -88.905 | 1.015.925 | -8,05 | 0,56 | -49.787 | 568.918 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -49.565 | 566.395 | -8,05 | 0,56 | -27.756 | 317.181 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -290.692 | 1.104.830 | -20,83 | 0,60 | -174.415 | 662.898 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -162.064 | 615.960 | -20,83 | 0,60 | -97.238 | 369.576 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -1.011 | 1.395.522 | -0,07 | 0,55 | -556 | 767.537 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -563 | 778.024 | -0,07 | 0,55 | -310 | 427.913 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -128.003 | 1.396.533 | -8,40 | 0,56 | -71.682 | 782.058 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -71.362 | 778.587 | -8,40 | 0,56 | -39.963 | 436.009 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -10.209 | 1.524.536 | -0,67 | 0,53 | -5.411 | 808.004 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -5.691 | 849.949 | -0,67 | 0,53 | -3.016 | 450.473 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -193 | 1.534.745 | -0,01 | 0,59 | -114 | 905.500 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -107 | 855.640 | -0,01 | 0,59 | -63 | 504.828 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -34.724 | 1.534.938 | -2,21 | 0,58 | -20.140 | 890.264 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -19.358 | 855.747 | -2,21 | 0,58 | -11.228 | 496.333 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -4.816 | 1.569.662 | -0,31 | 0,58 | -2.793 | 910.404 | |
2010-11-18 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2.684 | 875.105 | -0,31 | 0,58 | -1.557 | 507.561 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -3.690 | 2.902.743 | -0,13 | 7,55 | -27.860 | 21.915.710 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -2.605 | 2.050.745 | -0,13 | 7,55 | -19.668 | 15.483.125 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -900 | 689.900 | -0,13 | 7,55 | -6.795 | 5.208.745 | |
2010-11-05 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -516 | 423.901 | -0,12 | 7,55 | -3.896 | 3.200.453 | |
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
2.053.350 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
2.906.433 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
424.417 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
690.800 | ||||||||
2010-11-05 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
25.000 | ||||||||
2010-10-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -63.563 | 1.574.478 | -3,88 | 0,59 | -37.502 | 928.942 | |
2010-10-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -35.437 | 877.789 | -3,88 | 0,59 | -20.908 | 517.896 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -129 | 1.638.041 | -0,01 | 0,58 | -75 | 950.064 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -71 | 913.226 | -0,01 | 0,58 | -41 | 529.671 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -12.842 | 1.638.170 | -0,78 | 0,58 | -7.448 | 950.139 | |
2010-09-28 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -7.158 | 913.297 | -0,78 | 0,58 | -4.152 | 529.712 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -1.443 | 1.651.012 | -0,09 | 0,59 | -851 | 974.097 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -804 | 920.455 | -0,09 | 0,59 | -474 | 543.068 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2 | 1.652.455 | 0,00 | 0,58 | -1 | 958.424 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -28.553 | 1.652.457 | -1,70 | 0,59 | -16.846 | 974.950 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -15.917 | 921.259 | -1,70 | 0,59 | -9.391 | 543.543 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -4.559 | 1.681.010 | -0,27 | 0,58 | -2.644 | 974.986 | |
2010-09-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2.541 | 937.176 | -0,27 | 0,58 | -1.474 | 543.562 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -192.616 | 1.685.569 | -10,26 | 0,58 | -111.717 | 977.630 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -107.384 | 939.717 | -10,26 | 0,58 | -62.283 | 545.036 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -256.821 | 1.878.185 | -12,03 | 0,59 | -151.524 | 1.108.129 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -143.179 | 1.047.101 | -12,03 | 0,59 | -84.476 | 617.790 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -40.129 | 2.135.006 | -1,84 | 0,60 | -24.077 | 1.281.004 | |
2010-09-17 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -22.371 | 1.190.280 | -1,84 | 0,60 | -13.423 | 714.168 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -3.780 | 2.175.135 | -0,17 | 0,89 | -3.364 | 1.935.870 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -2.107 | 1.212.651 | -0,17 | 0,89 | -1.875 | 1.079.259 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -642.053 | 2.178.915 | -22,76 | 0,78 | -500.801 | 1.699.554 | |
2010-08-23 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
S - Sale | -357.947 | 1.214.758 | -22,76 | 0,78 | -279.199 | 947.511 | |
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock Warrants (right to buy) |
P - Purchase | 1.544.750 | 1.544.750 | 0,12 | 193.094 | 193.094 | ||
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock Warrants (right to buy) |
P - Purchase | 876.489 | 876.489 | 0,12 | 109.561 | 109.561 | ||
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
P - Purchase | 1.626.053 | 2.820.968 | 136,08 | 2,00 | 3.252.106 | 5.641.936 | |
2009-09-11 |
|
4 | NURO |
NeuroMetrix, Inc.
Common Stock |
P - Purchase | 922.620 | 1.572.705 | 141,92 | 2,00 | 1.845.240 | 3.145.410 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -133.445 | 2.941.480 | -4,34 | 13,16 | -1.756.136 | 38.709.877 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -66.555 | 1.928.520 | -3,34 | 13,16 | -875.864 | 25.379.323 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -33.361 | 3.074.925 | -1,07 | 13,06 | -435.695 | 40.158.520 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -16.639 | 1.995.075 | -0,83 | 13,06 | -217.305 | 26.055.680 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -200.168 | 3.108.286 | -6,05 | 13,01 | -2.604.186 | 40.438.801 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -99.832 | 2.011.714 | -4,73 | 13,01 | -1.298.814 | 26.172.399 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -64.720 | 3.308.454 | -1,92 | 13,49 | -873.073 | 44.631.044 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -32.280 | 2.111.546 | -1,51 | 13,49 | -435.457 | 28.484.756 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -41.980 | 3.373.174 | -1,23 | 13,06 | -548.259 | 44.053.652 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -20.937 | 2.143.826 | -0,97 | 13,06 | -273.437 | 27.998.368 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -22.782 | 3.415.154 | -0,66 | 13,32 | -303.456 | 45.489.851 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -11.361 | 2.164.763 | -0,52 | 13,32 | -151.329 | 28.834.643 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -145.704 | 3.437.936 | -4,07 | 12,98 | -1.891.238 | 44.624.409 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -25.000 | 3.583.640 | -0,69 | 12,96 | -324.000 | 46.443.974 | |
2009-09-10 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -111.189 | 3.608.640 | -2,99 | 12,98 | -1.443.233 | 46.840.147 | |
2009-08-20 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -10.921 | 3.719.829 | -0,29 | 12,98 | -141.755 | 48.283.380 | |
2009-08-20 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -70.000 | 3.730.750 | -1,84 | 12,96 | -907.200 | 48.350.520 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | 14.852 | 3.800.750 | 0,39 | 12,55 | 186.393 | 47.699.412 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -9.901 | 2.176.124 | -0,45 | 12,55 | -124.258 | 27.310.356 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | 113.182 | 3.815.602 | 3,06 | 12,98 | 1.469.102 | 49.526.514 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -75.448 | 2.186.025 | -3,34 | 12,98 | -979.315 | 28.374.604 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -86.540 | 3.928.784 | -2,16 | 13,11 | -1.134.539 | 51.506.358 | |
2009-07-29 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
S - Sale | -57.689 | 2.261.473 | -2,49 | 13,11 | -756.303 | 29.647.911 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 21.588 | 3.957.249 | 0,55 | 8,54 | 184.362 | 33.794.906 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 12.462 | 2.285.637 | 0,55 | 8,54 | 106.425 | 19.519.340 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 22.190 | 3.935.661 | 0,57 | 8,87 | 196.825 | 34.909.313 | |
2009-01-02 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 12.810 | 2.273.175 | 0,57 | 8,87 | 113.625 | 20.163.062 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 63.401 | 3.913.471 | 1,65 | 8,47 | 537.006 | 33.147.099 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 36.599 | 2.260.365 | 1,65 | 8,47 | 309.994 | 19.145.292 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 5.326 | 3.850.070 | 0,14 | 8,47 | 45.111 | 32.610.093 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 3.074 | 2.223.766 | 0,14 | 8,47 | 26.037 | 18.835.298 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 126.800 | 3.844.744 | 3,41 | 8,52 | 1.080.336 | 32.757.219 | |
2008-12-31 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 73.200 | 2.220.692 | 3,41 | 8,52 | 623.664 | 18.920.296 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 381 | 3.717.944 | 0,01 | 8,54 | 3.254 | 31.751.242 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 219 | 2.147.492 | 0,01 | 8,54 | 1.870 | 18.339.582 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 3.424 | 3.717.563 | 0,09 | 8,33 | 28.522 | 30.967.300 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 1.976 | 2.147.273 | 0,09 | 8,33 | 16.460 | 17.886.784 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 57.061 | 3.714.139 | 1,56 | 8,40 | 479.312 | 31.198.768 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 32.939 | 2.145.297 | 1,56 | 8,40 | 276.688 | 18.020.495 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 28.471 | 3.657.078 | 0,78 | 8,54 | 243.142 | 31.231.446 | |
2008-12-24 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 16.435 | 2.112.358 | 0,78 | 8,54 | 140.355 | 18.039.537 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 54.409 | 3.628.607 | 1,52 | 8,48 | 461.388 | 30.770.587 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 31.409 | 2.095.523 | 1,52 | 8,48 | 266.348 | 17.770.035 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 9.570 | 3.574.198 | 0,27 | 8,53 | 81.632 | 30.487.909 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 5.524 | 2.064.514 | 0,27 | 8,53 | 47.120 | 17.610.304 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 20.289 | 3.564.628 | 0,57 | 8,47 | 171.848 | 30.192.399 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 11.711 | 2.058.990 | 0,57 | 8,47 | 99.192 | 17.439.645 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 33.308 | 3.544.339 | 0,95 | 8,52 | 283.784 | 30.197.768 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 19.227 | 2.047.279 | 0,95 | 8,52 | 163.814 | 17.442.817 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 10.588 | 3.511.031 | 0,30 | 8,04 | 85.128 | 28.228.689 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 6.112 | 2.028.052 | 0,30 | 8,04 | 49.140 | 16.305.538 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 135.009 | 3.500.443 | 4,01 | 7,78 | 1.050.370 | 27.233.447 | |
2008-12-22 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
P - Purchase | 77.938 | 2.021.940 | 4,01 | 7,78 | 606.358 | 15.730.693 | |
2008-12-05 | 3 | NURO |
NeuroMetrix, Inc.
Common Stock |
650.085 | ||||||||
2008-12-05 | 3 | NURO |
NeuroMetrix, Inc.
Common Stock |
1.194.915 | ||||||||
2008-11-21 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
1.944.002 | ||||||||
2008-11-21 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
3.365.434 | ||||||||
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -131.836 | 881.743 | -13,01 | 0,24 | -31.641 | 211.618 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -56.957 | 503.348 | -10,17 | 0,24 | -13.670 | 120.804 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -128.800 | 1.013.579 | -11,27 | 0,26 | -33.488 | 263.531 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -71.200 | 560.305 | -11,27 | 0,26 | -18.512 | 145.679 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -34.431 | 1.142.379 | -2,93 | 0,44 | -15.150 | 502.647 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19.033 | 631.505 | -2,93 | 0,44 | -8.375 | 277.862 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -644 | 1.176.810 | -0,05 | 0,56 | -361 | 659.014 | |
2008-11-20 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -356 | 650.538 | -0,05 | 0,56 | -199 | 364.301 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -23.378 | 1.177.454 | -1,95 | 0,49 | -11.455 | 576.952 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -12.922 | 650.894 | -1,95 | 0,49 | -6.332 | 318.938 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -85.865 | 1.200.832 | -6,67 | 0,48 | -41.215 | 576.399 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -47.465 | 663.816 | -6,67 | 0,48 | -22.783 | 318.632 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -82.819 | 1.286.697 | -6,05 | 0,50 | -41.410 | 643.348 | |
2008-11-14 |
|
4 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
S - Sale | -45.781 | 711.281 | -6,05 | 0,50 | -22.890 | 355.640 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -276.493 | 0 | -100,00 | 0,24 | -66.358 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -56.742 | 276.493 | -17,03 | 0,22 | -12.636 | 61.575 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -533.176 | 333.235 | -61,54 | 0,27 | -141.771 | 88.607 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -138.370 | 0 | -100,00 | 0,24 | -33.209 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -28.395 | 138.370 | -17,03 | 0,22 | -6.324 | 30.815 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -266.824 | 166.765 | -61,54 | 0,27 | -70.949 | 44.343 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -195.563 | 0 | -100,00 | 0,24 | -47.228 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -225.156 | 195.563 | -53,52 | 0,23 | -50.930 | 44.236 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -317.000 | 420.719 | -42,97 | 0,24 | -75.858 | 100.678 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -41.123 | 737.719 | -5,28 | 0,23 | -9.339 | 167.536 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -95.100 | 778.842 | -10,88 | 0,28 | -26.580 | 217.686 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -63.400 | 873.942 | -6,76 | 0,25 | -15.850 | 218.486 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -96.075 | 937.342 | -9,30 | 0,25 | -23.961 | 233.773 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -1.001.720 | 1.033.417 | -49,22 | 0,26 | -257.342 | 265.485 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -125.000 | 0 | -100,00 | 0,24 | -30.625 | ||
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -329.437 | 125.000 | -72,49 | 0,24 | -79.559 | 30.188 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -129.981 | 454.437 | -22,24 | 0,23 | -29.402 | 102.794 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -183.000 | 584.418 | -23,85 | 0,24 | -43.792 | 139.851 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -23.740 | 767.418 | -3,00 | 0,23 | -5.391 | 174.281 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -54.900 | 791.158 | -6,49 | 0,28 | -15.345 | 221.129 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -36.600 | 846.058 | -4,15 | 0,25 | -9.150 | 211.514 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -55.463 | 882.658 | -5,91 | 0,25 | -13.832 | 220.135 | |
2008-10-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
S - Sale | -578.280 | 938.121 | -38,14 | 0,26 | -148.560 | 241.003 | |
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
S - Sale | -323.900 | 0 | -100,00 | ||||
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
S - Sale | -178.100 | 0 | -100,00 | ||||
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
J - Other | -460.400 | 0 | -100,00 | ||||
2008-10-21 |
|
4 | SLXP |
SALIX PHARMACEUTICALS LTD
Call Options |
J - Other | -264.600 | 0 | -100,00 | ||||
2008-10-14 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
1.665.842 | ||||||||
2008-10-14 | 3 | SLXP |
SALIX PHARMACEUTICALS LTD
Common Stock |
2.883.594 | ||||||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 105.300 | 105.300 | |||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 61.300 | 61.300 | |||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 519.200 | 519.200 | |||||
2008-06-30 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 314.200 | 314.200 | |||||
2008-03-14 | 3 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
757.062 | ||||||||
2008-03-14 | 3 | CYCC |
Cyclacel Pharmaceuticals, Inc.
Common Stock |
1.369.516 | ||||||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 136.890 | 136.890 | |||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 79.960 | 79.960 | |||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 674.960 | 674.960 | |||||
2007-11-01 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 408.460 | 408.460 | |||||
2007-10-23 |
|
4 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
S - Sale | -15.875 | 3.238.908 | -0,49 | 10,51 | -166.805 | 34.032.502 | |
2007-10-23 |
|
4 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
S - Sale | -9.125 | 1.861.735 | -0,49 | 10,51 | -95.880 | 19.561.994 | |
2007-10-23 | 3 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
1.870.860 | ||||||||
2007-10-23 | 3 | ARNA |
ARENA PHARMACEUTICALS INC
Common Stock |
3.254.783 | ||||||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 131.625 | 131.625 | |||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 76.625 | 76.625 | |||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 649.000 | 649.000 | |||||
2007-07-23 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 392.750 | 392.750 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 131.625 | 131.625 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 76.625 | 76.625 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 649.000 | 649.000 | |||||
2007-07-20 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Warrants |
P - Purchase | 392.750 | 392.750 | |||||
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 376.185 | 2.035.137 | 22,68 | 4,40 | 1.655.214 | 8.954.603 | |
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 257.122 | 1.516.401 | 20,42 | 4,40 | 1.131.337 | 6.672.164 | |
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 105.142 | 433.589 | 32,01 | 4,40 | 462.625 | 1.907.792 | |
2006-10-06 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 211.551 | 866.411 | 32,30 | 4,40 | 930.824 | 3.812.208 | |
2006-05-17 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 24.100 | 328.447 | 7,92 | 5,50 | 132.543 | 1.806.360 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 24.100 | 327.447 | 7,94 | 5,50 | 132.543 | 1.800.860 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 63.565 | 654.860 | 10,75 | 5,50 | 349.588 | 3.601.534 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 10.246 | 591.295 | 1,76 | 5,50 | 56.345 | 3.251.649 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 3.226 | 581.049 | 0,56 | 5,12 | 16.501 | 2.972.066 | |
2006-05-15 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.602 | 304.347 | 0,53 | 5,12 | 8.194 | 1.556.735 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 11.200 | 577.823 | 1,98 | 5,71 | 63.945 | 3.299.023 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 200 | 302.745 | 0,07 | 5,71 | 1.142 | 1.728.492 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5.211 | 566.623 | 0,93 | 5,72 | 29.785 | 3.238.704 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 2.589 | 302.545 | 0,86 | 5,72 | 14.798 | 1.729.287 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 28.701 | 1.658.952 | 1,76 | 5,50 | 157.856 | 9.124.236 | |
2006-05-02 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 21.299 | 1.259.279 | 1,72 | 5,50 | 117.144 | 6.926.034 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.549 | 540.673 | 0,29 | 6,02 | 9.319 | 3.252.851 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 768 | 289.650 | 0,27 | 6,02 | 4.621 | 1.742.621 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 13.180 | 1.566.513 | 0,85 | 6,02 | 79.295 | 9.424.612 | |
2006-04-24 |
|
4/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 9.779 | 1.190.678 | 0,83 | 6,02 | 58.833 | 7.163.476 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 12.065 | 561.412 | 2,20 | 5,55 | 66.964 | 3.116.005 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5.996 | 299.956 | 2,04 | 5,55 | 33.280 | 1.664.846 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 31.102 | 1.630.251 | 1,94 | 5,55 | 172.625 | 9.048.382 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 23.082 | 1.237.980 | 1,90 | 5,55 | 128.112 | 6.871.160 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 6.680 | 549.347 | 1,23 | 5,43 | 36.297 | 2.984.987 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 3.320 | 293.960 | 1,14 | 5,43 | 18.040 | 1.597.290 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 17.220 | 1.599.149 | 1,09 | 5,43 | 93.568 | 8.689.296 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 12.780 | 1.214.898 | 1,06 | 5,43 | 69.443 | 6.601.391 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.994 | 542.667 | 0,37 | 5,48 | 10.923 | 2.972.784 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 990 | 290.640 | 0,34 | 5,48 | 5.423 | 1.592.155 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 15.416 | 1.581.929 | 0,98 | 5,48 | 84.450 | 8.665.965 | |
2006-04-24 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 11.440 | 1.202.118 | 0,96 | 5,48 | 62.669 | 6.585.323 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 13.180 | 552.304 | 2,44 | 6,02 | 79.295 | 3.322.827 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 9.779 | 298.661 | 3,39 | 6,02 | 58.833 | 1.796.834 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.549 | 1.554.882 | 0,10 | 6,02 | 9.319 | 9.354.637 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 768 | 1.181.667 | 0,07 | 6,02 | 4.621 | 7.109.263 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.761 | 539.124 | 0,33 | 6,03 | 10.626 | 3.253.182 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 874 | 288.882 | 0,30 | 6,03 | 5.274 | 1.743.172 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 26.678 | 1.553.333 | 1,75 | 6,03 | 160.980 | 9.373.122 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 19.796 | 1.180.899 | 1,70 | 6,03 | 119.453 | 7.125.781 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 32.132 | 537.363 | 6,36 | 6,03 | 193.804 | 3.241.105 | |
2006-04-05 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 15.968 | 288.008 | 5,87 | 6,03 | 96.311 | 1.737.120 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.122 | 505.231 | 0,22 | 5,91 | 6.630 | 2.985.663 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 603 | 272.040 | 0,22 | 5,91 | 3.563 | 1.607.620 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 7.248 | 1.526.655 | 0,48 | 5,91 | 42.832 | 9.021.768 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5.511 | 1.161.103 | 0,48 | 5,91 | 32.567 | 6.861.538 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 2.938 | 504.109 | 0,59 | 6,02 | 17.694 | 3.035.946 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.581 | 271.437 | 0,59 | 6,02 | 9.521 | 1.634.702 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 18.981 | 1.519.407 | 1,27 | 6,02 | 114.311 | 9.150.477 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 14.434 | 1.155.592 | 1,26 | 6,02 | 86.927 | 6.959.437 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5.281 | 501.171 | 1,06 | 5,95 | 31.439 | 2.983.621 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 2.843 | 269.856 | 1,06 | 5,95 | 16.925 | 1.606.534 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 34.119 | 1.500.426 | 2,33 | 5,95 | 203.121 | 8.932.486 | |
2006-03-17 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 25.948 | 1.141.158 | 2,33 | 5,95 | 154.476 | 6.793.656 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 1.185 | 495.890 | 0,24 | 6,03 | 7.144 | 2.989.423 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 638 | 267.013 | 0,24 | 6,03 | 3.846 | 1.609.661 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 7.655 | 1.466.307 | 0,52 | 6,03 | 46.147 | 8.839.485 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5.822 | 1.115.210 | 0,52 | 6,03 | 35.097 | 6.722.932 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 11.375 | 494.705 | 2,35 | 6,00 | 68.250 | 2.968.230 | |
2006-03-09 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 6.125 | 266.375 | 2,35 | 6,00 | 36.750 | 1.598.250 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 9.840 | 483.330 | 2,08 | 5,90 | 58.068 | 2.852.227 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 5.295 | 260.250 | 2,08 | 5,90 | 31.247 | 1.535.787 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 59.128 | 1.458.652 | 4,22 | 5,90 | 348.926 | 8.607.797 | |
2006-03-07 |
|
4 | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
P - Purchase | 44.967 | 1.109.388 | 4,22 | 5,90 | 265.359 | 6.546.720 | |
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
993.599 | ||||||||
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
245.000 | ||||||||
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
1.306.401 | ||||||||
2006-03-07 | 3/A | DVAX |
DYNAVAX TECHNOLOGIES CORP
Common Stock |
455.000 |